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Abstract	  
(A) In recent years, 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) fluorophores have 
attracted considerable interest due to their unique photochemical properties. However detailed 
studies on the stability of BODIPY and analogues under acidic and basic conditions have 
been lacking. Thus the stability of a series of BODIPY analogues in acidic (di- and 
trichloroacetic acid) and basic (aqueous ammonium hydroxide) conditions was investigated 
using 11B NMR spectroscopy. Among the analogues tested, 4,4-diphenyl BODIPY was the 
most stable under the conditions used in the experiments. It was found that reaction of 4,4-
dimethoxy BODIPY with dichloroacetic acid gave mixed anhydride 4,4-bis(dichloroacetoxy) 
BODIPY in good yields. Treatment of the latter mixed anhydride with alcohols such as 
methanol and ethanol in the presence of a base afforded corresponding borate esters, whereas 
treatment with 1,2-diols such as ethylene glycol and catechol in the presence of a base gave 
corresponding cyclic borate esters. Furthermore treatment of 4,4-difluoro-8-methyl-BODIPY 
with secondary amines in dihalomethane resulted in carbon–carbon bond formation at the 
meso-methyl position of BODIPY via Mannich-type reactions. The resulting modified 
BODIPY fluorophores possess high fluorescent quantum yields.  Five BODIPY analogues 
bearing potential ion-binding moieties were synthesized via this Mannich-type reaction. 
Among these, the BODIPY bearing an aza-18-crown-5 tether was found to be selective 
towards copper (II) ion, resulting in a large blue shift in absorption and sharp fluorescent 
quenching, whereas aza-15-crown-4 analogue was selected towards fluoride ion, leading to 
effective florescent quenching and blue shift. 
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(B) Peptide nucleic acids (PNA), as mimics of natural nucleic acids, have been widely applied 
in molecular biology and biotechnology. Currently, the preparation of PNA oligomers is 
commonly achieved by a coupling reaction between carboxyl and amino groups in the 
presence of an activator. In this thesis attempts were made towards the synthesis of PNA 
through the Staudinger ligation reactions between C-terminal diphenylphosphinomethanethiol 
thioesters and N-terminal α-azido PNA building blocks.  
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Chapter 1 BODIPY as a versatile fluorophore 
1.1 Introduction to fluorophores 
Fluorescence is a property of a substance that allows it to emit light upon exposure to at a 
higher frequency light. Since Sir John Frederick William Herschel reported the first 
observation of fluorescence from a quinine solution in sunlight in 1845,[1] fluorescence has 
been widely applied in diverse practical usages, such as chemical sensors, mineralogy, 
fluorescent labeling, dyes, and biological detectors. Fluorescence spectroscopy, fluorescence 
imaging and fluorescence indicators are indispensable tools in various fields of modern 
science and medicine, including clinical diagnostics, molecular biology, biochemistry, 
materials science, and environmental chemistry.[2] In biological assays and medical diagnosis 
in particular, fluorescence methods have attracted increasing interests over the past few 
years.[3] Specific fluorescent reporters have been designed to combine with recognition sites, 
which enable researchers to detect components of complex biomolecular assemblies with high 
sensitivity.[4] Thus, fluorescence methods have become alternatives to radioactive labeling, 
especially for sensing and visualization of analytes inside living cells.[5] 
Among the numerous fluorophores reported to date, the principal classes are based on 
fluorescein, rhodamine, cyanine and difluoro-bora-indacene family (4,4-difluoro-4-bora-3a-
azonia-4a-aza-s-indacene, abbreviated hereafter as F-BODIPY) (Figure 1-1).  
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Figure 1-1. Organic fluorescent dyes structures 
1.2 Introduction to borondipyrromethene difluoride (BODIPY) 
Among various types of highly fluorescent dyes, the BODIPY-class fluorophore has 
earned increasing interest as a versatile heterocyclic skeleton fluorophore. The first members 
of BODIPY derivatives were reported by Alfred Treibs and Franz-Heinrich Kruezer at 1968.[6] 
However, more attention was given to the BODIPY based-dyes and their potential 
applications in biological labeling in the late 1980s.[7, 8] Biological labeling with BODIPY 
was not implemented until 1989 when BODIPY labeled ligands were first synthesized as 
highly selective D1 and D2 dopaminergic probes.[9] In the past 2-3 decades, due to their 
unique photochemical and photophysical properties, there have been enormous research 
interests on the BODIPY fluorophores, which is reflected by the number of patents and 
journal articles on the syntheses and applications of BODIPY-based dyes. Over 700 patents 
and 1000 journal articles had been published by 2006.[10] 
The IUPAC name of BODIPY is 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene by analogy 
to the all-carbon tricyclic s-indacene ring system (Figure 1-2). Hence, rules for numbering 
any substituents on the BODIPY core structure are the same as the carbon polycycle. On the 
other hand, BODIPY can also be regarded as an analogue of ‘dipyrrin core’, and thus, the 
terms α-, β-, and meso-position are applicable to both BODIPY and dipyrrin systems (Figure 
1-2).[11]  
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Figure 1-2. Numbering schemes used for the dipyrromethenes and BODIPY framework derived from 
indacene. 
BODIPY-based fluorophores exhibit extraordinary optical properties, such as high molar 
extinction coefficients, high fluorescent quantum yields, sharp excitation and emission peaks, 
and small Stock’s shifts.[12] Moreover, they are relatively stable thermally, chemically and 
photochemically, while they are fairly insensitive to solvent polarity and pH.[12] Therefore, 
BODIPY-based fluorophores are superior to other fluorophores in some applications,[12, 13]  
and have shown dramatic growth in popularity. 
In general, the majority of BODIPY-based dyes are substituted. Fully unsubstituted 
BODIPY core was not prepared until 2009 by three independent groups.[14] The main obstacle 
in the synthesis of this fully unsubstituted BODIPY core structure relates to the instability of 
the fully unsubstituted dipyrromethene precursor.[14]  
BODIPY derivatives are also associated with certain drawbacks that limit their 
applications. Among these, narrow Stoke’s shift, poor water solubility and lack of functional 
groups for conjugation are commonly cited limitations.[15] Through the introduction of 
various substituents on the 2-, 3-, 5-, 6-, and meso-positions, properties of BODIPY can be 
modulated to suit various applications.  
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1.3 General synthesis of BODIPY 
A number of approaches have been reported for the synthesis and modification of the 
BODIPY fluorophore. The most well-known route for the preparation of the BODIPY 
fluorophore begins with condensation of acyl chlorides 2 with pyrroles 1 to yield the unstable 
dipyrromethene hydrochloride salt intermediates 3, which subsequently undergoes 
complexation with borontrifluoride in the presence of a base such as triethylamine and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) (Scheme 1-1).[16] This approach is particularly suited 
for the synthesis of symmetric BODIPY dyes 4. Isolation of the unstable intermediate 
dipyrromethene hydrochlorides 3 is quite difficult, however, the intermediates 3 become 
easier to handle with the increasing number of the C-substituents. Nevertheless, these 
intermediates 3 are rarely isolated during the synthesis of BODIPY. 
 
Scheme 1-1: Reagents and conditions: i) NEt3, iPr2EtN or DBU; (ii) BF3·Et2O, toluene or CH2Cl2. 
Acid anhydrides such as glutaric anhydride and succinic anhydride have been used as an 
alternative of acyl chlorides in the synthesis of BODIPY fluorophores.[17] BODIPY derivative 
7 was generated from succinic anhydride 6 and pyrrole fragment 5. (Schemem1-2) This 
chemistry is particularly useful for the preparation of BODIPY with a free carboxyl group 
that can be further conjugated to targeted molecules. 
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Scheme 1-2: Reagents and conditions: i) BF3·Et2O; (ii) NEt3, BF3·Et2O. 
Alternatively, aldehyde 9 can be used in place of acyl chloride or anhydride as the 
electrophilic carbonyl substrate. Thus, dipyrromethane intermediate 10 can be formed by 
condensation of pyrrole 8 and aldehyde 9 in the presence of an acid. The dipyrromethane 
intermediate 10 needs to be further oxidized into the corresponding dipyrromethene followed 
by complexation with borontrifluoride in the presence of a base (Scheme 1-3). Although this 
synthetic strategy involves more steps, it is still commonly used owing to the stability of 
dipyrromethane.  
 
Scheme 1-3: Reagents and conditions: i) H+, CH2Cl2; ii) (a) 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (DDQ), 
(b) NEt3, BF3·Et2O. 
Wu’s group reported a novel approach towards the synthesis of BODIPY framework 
(Scheme 1-4).[18] In the presence of excess phosphorus oxychloride, pyrrole-2-carbaldehyde 
derivatives 12 are condensed to form dipyrromethene dichlorophosphate salt intermediates 13. 
Without further purification, the intermediates were treated with a base and borontrifluoride 
to generate the target symmetric BODIPY derivatives 14 unsubstituted at the meso-position in 
high yields.  
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Scheme 1-4: Reagents and conditions: i) POCl3, CH2Cl2, room. temp., 12 h; ii) NEt3, BF3·Et2O, room. temp., 12 
h. 
Routes outlined above are convenient strategies to obtain symmetrically substituted 
BODIPY dyes. Asymmetric BODIPY fluorophore 17 can usually be obtained by the 
MacDonald coupling approach (Scheme 1-5), via the condensation reaction of a carbonyl-
containing pyrrole 15 with pyrrole 16 that is unsubstituted at the α-position. Yields for the 
MacDonald reaction are generally high. However, dramatically reduced yields are often 
observed when the α-free pyrroles are electron-deficient.[19] In the latter case, the favored 
reaction is the self-condensation of pyrrole-2-carbaldehyde derivatives, and undesired 
symmetric BODIPYs are always isolated as the major products.[19] Overall the main 
advantage of this strategy is the possibility to functionalize BODIPYs on pyrrole carbocycles 
side chains, which enables them to be further derivatized or attached to other 
macromoleculars. 
 
Scheme 1-5: Reagents and conditions: i) H+, CH2Cl2; ii) NEt3, BF3·Et2O. 
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1.4 Fluorescent properties of BODIPY 
Fluorophores have several important characteristics such as fluorescence lifetime, 
quantum yield, maximum absorption and emission wavelengths, Stoke’s shift and molar 
extinction coefficient. In general these properties are readily influenced by the structures of 
fluorophores, some of which are described below. 
1.4.1 General structural features of fluorophores 
Fluorophores typically contain rigid frame structures that have combined aromatic groups, 
planar or cyclic structures with elongated conjugated π systems. The fluorescence properties 
are influenced by several factors, such as π-electron conjugation, structural rigidity, and the 
type and position of substituents on the molecules. 
1). Increasing π-electron conjugation normally leads to enhanced fluorescent emission and 
red-shifts in excitation and emission wavelengths. By modifying the conjugation system, 
possible decrease or enhancement of quantum yield can be observed. 
2). Introducing steric constraints to the molecular structure normally enhances the 
fluorescence quantum yield. The increased rigidity, induced by conformational restriction, 
reduces the rotation and distortion of the molecule, which accounts for increases in quantum 
yields.[20]   
1.4.2 Structural modification of BODIPY 
BODIPY fluorophores, with a rigid core structure, quite commonly possess extraordinary 
photochemical and photophysical properties. A wide range of structural modifications, 
tailoring the fluorescent properties, have been performed on the BODIPY fluorophore. 
Selected BODIPY analogues with extended conjugation systems and with modifications on 
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rigidity and the boron centre will be discussed herein. 
1.4.2.1 Extension on π-conjugation systems  
Some researchers successfully extended the π-conjugation systems to red-shift the 
excitation and emission wavelengths of BODIPY dyes.[21-24] Several strategies can be used to 
expand the conjugation, including synthesizing the di(isoindole)methane dyes [21a, 21b] or 
attaching ethynylphenyl, styryl, vinyl, aromatic ring substitutions to the framework.[22] A 
handful of publications have been reported to utilize Retro-Diels Alder reaction to access the 
highly conjugated BODIPY analogues.[21a, 23] Mitasuo et. al.[21a] reported that the isoindole-
BODIPY dyes 18 (Figure 1-3) could be generated via a retro-Diels–Alder reaction from 
bicyclo[2.2.2]octadiene fused BODIPY precursors.  A few years later, the same group 
prepared a new class of π-expanded BODIPYs from the precursor dyes fused with benzene, 
acenaphthylene, and benzofluoranthene by the same strategy.[23] Other than the retro-Diels-
Alder reaction, some other routes have been utilized to prepare isoindole-based BODIPY 
derivatives that exhibit fluorescence absorptions and emissions in visible or near-infrared 
region. As reported, substituted 2-acylacetophenone was condensed with ammonia to give the 
dibenzopyrromethene and the corresponding product was then treated with boron trifluoride 
diethyl etherate to generate the targeted BODIPY 19 with 3,4,3’,4’-
dibenzopyrrometheneboron difluoride core.[24a] Another interesting example with extended 
conjugation system, compound 20, can be obtained by condensation of 2-methylthiobenz-
[c,d]indolium iodide and 2-methylbenz[c,d]indolium iodide, respectively, followed by 
addition of a base and complexation with boron trifluoride diethyl etherate.[24b] The 
corresponding product has fixed planar structure, exhibiting a sharp absorption band at 618 
nm and emission band at 625 nm. 
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Figure 1-3. BODIPY dyes with extended conjugations 
Interestingly, aryl substitution at the meso-position does not substantially alter the 
maximal absorption and emission profile[11] while substitution at the α-positions of BODIPY 
can effectively shift the absorption and emission wavelengths.[22]  
1.4.2.2 Restricted systems 
As mentioned above, arylation at the meso-position has no specific effect on the 
absorption and emission wavelength while the quantum yield of the meso-phenyl compound 
suffered a significant reduction when free rotation of the aryl group is allowed.[11] However, 
high fluorescence quantum yields can be restored by introducing methyl groups to the β-
positions of the BODIPY framework (Figure 1-4: compare 21 with 22). In fact, blocking the 
1,7-positions can inhibit the free rotation of the phenyl group, which consequently reduces 
loss of energy from the excited states via non-irradiative molecular motions. Consistent with 
this, greatly enhanced quantum yields also can be observed through introducing ortho-
substituents on the phenyl ring 23, and similar explanations have been invoked. (Figure 1-4: 
compare 21 with 23)  Consequently, increasing the rigidity of the BODIPY structure is an 
efficient strategy to obtain the high fluorescence intensity. 
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Figure 1-4 Effects of meso-aryl substitution of the fluorescence of BODIPY. Reduced quantum yields are 
observed in unsubstituted meso-aryl BODIPYs 
 
Figure 1-5 BODIPY dyes with rigid structure 
Kevin Burgess’ lab[25] prepared a series of BODIPY dyes with more rigid conformations 
in which the aryl substituents and 2, 6-position of the BODIPYs have been linked through a 
heteroatom or ethylene bridge precluding free rotation of the substituted-benzene molecular 
fragments. These dyes exhibit visible excitation and emission wavelengths [ (620-660 
nm), λmax
em (630-680 nm)] and high fluorescent quantum yields (up to 0.72 for 24). Another 
novel modification on the rigidity has been shown by the same group. The aryl-substituted 
dye is constrained through an ether bond linkage between the boron center and aryl groups. 
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The constrained dye 25 [26] exhibits a sharper, red-shifted fluorescence emission that is more 
intense than the precursor analogue with aryl groups rotating freely. 
1.4.2.3 Modification at the boron center 
Replacement of the two fluorine atoms in BODIPYs provide a novel strategy to generate 
a new family of BODIPYs, which is considered as an alternative way to modify some optical 
properties of BODIPYs (Figure 1-6). Aryl displacements on the boron-fluorine bond 
(compound 26) entity can efficiently extend the conjugation system,[27] which was first 
reported in Murase’s patent.[27a] The novel approach was further exploited by Ulrich and his 
co-workers in developing BODIPY derivatives with aryl, ethynylaryl (compound 27), and 
ethynyl subunits in place of fluorine atoms.[27b, c] Compared with the F-BODIPY, these aryl-
BODIPY dyes show red-shifted excitation and emission wavelengths with minimal loss of 
fluorescence. Afterwards, more work has been reported on BODIPY analogues where 
fluorine is replaced with alkyl,[28] aryloxy, alkoxy (compound 28) and hydroxyl groups.[29] 
Conducting substitution reactions at the boron center has dramatically increased the versatility 
of BODIPY type fluorophores. 
 
Figure 1-6 Structures and fluorescent properties of BODIPY derivatives with variation on boron substituent  
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1.4.2.4 Commercially available BODIPY dyes covering the visible spectrum 
 
Figure 1-7 Chemical strutures of commercially available BODIPY fluorophores spanning the visible 
spectrum. 
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 Structure Analogue 
1 29 BODIPY FL 
2 30 BODIPY R6G 
3 31 BODIPY TMR 
4 32 BODIPY 581/591 
5 33 BODIPY TR 
6 34 BODIPY 630/650 
7 35 BODIPY 650/665 
Figure 1-8 Normalized fluorescence emission spectra of BODIPY derivatives in methanol.[12]  
α-Substituted conjugated systems can effectively shift the maximal emission wavelength. 
Compounds 29-35 (Figure 1-7), covering the majority of the visible spectrum (Figure 1-8), 
are commercially available BODIPY from Invitrogen. 
1.5 Applications of BODIPY dye 
        Synthesis of BODIPY fluorophores was first reported in 1968.[6] However, their 
applications as fluorescent sensors or labels only became common practice some twenty years 
later. Some applications of the BODIPY fluorophores are summarized below.  
1.5.1 Chemosensor 
Fluorescent sensing is a very useful approach in the detection and quantification of 
specific molecules and in imaging, and thus fluorescent sensors play a critical role in research 
geared towards the understanding of chemical and biological systems. To this end, BODIPY 
dyes have been synthesized as candidates for selective sensor of cations,[34-44]  anions,[46-49, 51] 
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redox active molecules,[52-54, 56, 59-61] pH probes[64, 65] and probes for biomolecules such as 
peptides, proteins, lipids and nucleic acids.[66-69] 
1.5.1.1 Metal ion sensors 
Metal ions are involved in diverse biological processes.[30] Heavy metal ions, such as lead, 
cadmium and mercury ions, can cause adverse health effects upon exposure.[31] Besides, these 
heavy metal ions can accumulate in the environment, leading to contamination in food and 
water.[32] Fluorescence is a simple and inexpensive method to detect and quantify heavy metal 
ions in real-time monitoring of environmental, biological, and industrial samples.[33] To this 
end, sensitive and selective BODIPY sensors (Figure 1-9) have been developed for 
fluorometric analysis for ions such as Pb2+,[34] Ag+,[35] Hg2+, [35 b, 36] and Cd+.[37] 
 
Figure 1-9 Structures of some BODIPY heavy metal ion sensors 
Compound 36[34 c] was designed as an “off-on” mercury sensor, exhibiting a selective 
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chelation enhanced fluorescence (CHEF) effects with Pb2+. The dramatic enhancement of 
fluorescence was owing to the blocking of the photoinduced electron transfer (PET) process. 
Similarly, the thio-aza-crown chemosensor 38 [36d] was found to selectively detect Hg2+ by an 
“off-on” type effect. Selective Hg2+ ion chemosensor 37, however, exhibits pronounced Hg2+ 
selective on-off-type fluoroionophoric properties. Thus, the fluorescence of compound 37 can 
be efficiently quenched by more than 98% with addition of five molar equivalents of Hg2+ 
ions.[36c] Binding of 37 to Hg2+ ions is also accompanied by a color change from light amber 
to red that is visible to the naked eye. It is noted that most chemosensors display changes in 
fluorescent intensity, while only very few of them can exhibit spectral shifts in either 
excitation or emission. Binding of 39 to Ag+ results in a concentration-dependent red-shift in 
emission from 630 to 670 nm, accompanied by fluorescent enhancement upon binding.[35a] 
 
Figure 1-10 Structures of some BODIPY Na+, K+, Ca2+, Zn2+, Fe3+ metal ion sensors 
Other metal ions such as alkali, alkaline earth metal and other transition metal ions are 
abundant in living organisms for different functions.[38] For instance, alkali metal ions, such 
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as Na+ and K+, are crucial in establishing and regulating cellular membrane potentials. Ca2+ 
ions play an important role in living organisms, where they can function as regulators 
for many enzymes and proteins. Besides, Zn2+, Ca2+ or Fe3+ ions have irreplaceable 
effects on biological structures and activities. Thus, a variety of fluorescent indicators for 
ions, such as Na+,[39] K+,[40] Ca2+,[41] Cu2+,[34c, 42] Zn2+,[43] or Fe3+[44] have been designed 
(Figure 1-10). Most of these fluorophore-receptor systems are based on either photoinduced 
electron transfer (PET) or internal charge transfer (ICT) processes. In sensor 41, PET is 
inhibited upon binding to Zn2+, leading to increase in fluorescence intensity.[43a] Ionophore 42 
shows a selective ‘on-off’ type quenching in response to Ca2+ due to the PET effect. 
Generally PET-based sensors show fluorescence intensity changes upon binding to non-metal 
ligands without significant shifts in the absorption and emission spectra.[41] Binding of metal 
ions, however, often leads to spectral shifts in addition to changes in emission intensity. For 
example, fluoroionophore 45 exhibits a red shift in the absorption maximum by 12 nm in the 
presence of Na+ ions, which is likely due to conformational changes, induced by the 
formation of 45-Na+ complex.[39a] Similarly, a considerable conformational change of K+ 
sensor 44 can be observed upon K+ ion binding, leading to a large (em and ex) wavelength 
shift.[40b] Some fluorescent indicators show changes in fluorescent properties through the 
formation of new compounds. Ferric ion sensor 43,[44a] for example, displays high sensitivity 
and selectivity for Fe3+ both in aqueous solution and living cells, showing turn-on 
fluorescence upon addition of ferric salts. It was presumed that this effect was based on 
quenching of PET affected by the hydroxylamine oxidation reaction.   
1.5.1.2 Anion sensors 
Much like cations, anions also play crucial roles in diverse essential biological 
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processes.[45] To this end, numerous fluorescent sensors have been developed for anions. 
Some BODIPY-derived anion indicators for F − ,[46] CN − ,[47] HSO 4
− ,[48] SO 3
2− ,[50] and HPO 4
2−
[51] are described in this section (Figure 1-11). 
Compound 46[48] was synthesized as a highly selective ‘off–on’ fluorescent sensor for 
hydrogen sulfate anion (HSO 4
− ) in neat and aqueous acetonitrile. In neat CH3CN, the ‘switch 
on’ process was due to the suppression of PET by forming hydrogen binding between the 
HSO 4
− 	  and the -C=N- of the receptor 46. In aqueous acetonitrile, fluorescent changes can be 
explained by the protonation of N atom (-N=C), leading to the inhibition of the PET process. 
 
Figure 1-11 Structures of some BODIPY-based anion sensors 
        Cyanide, an extremely toxic species, is used in various industrial processes. Some 
BODIPY derivatives have been synthesized as excellent cyanide anion indicators (Figure 1-
11). For instance, compound 47[47b] displays fluorescence turn-on in the presence of cyanide. 
The delocalization of the lowest unoccupied molecular orbital (LUMO) over the phenyl and 
dicyano-vinyl groups results in the photo-induced intramolecular charge transfer (ICT) from 
BODIPY to dicyano-vinyl groups. The π-conjugation between phenyl and dicyano-vinyl 
groups can be interrupted by the attacking of cyanide on the olefinic carbon, which leads to 
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fluorescence switch on.   
 Sulfites are commonly used as preservatives or enhancers in food and beverage industry. 
However sulfite may cause asthma attacks or other allergic reactions in hypersensitive 
persons.[49]  A few BODIPY-based fluorescent sulfite sensors have been prepared for the 
identification and quantification of sulfites. For instance, compound 48,[50] an indole-
BODIPY based sulfite dictator, shows a ratiometric and colorimetric response to sulfite ions 
through an irreversible chemical transformation. The levulinyl protected BODIPY could be 
easily and selectively deprotected by sulfites. As a result, the corresponding BODIPY 
derivative displays a red shift in absorption and a dramatic color change from orange to blue. 
 Another example of anion sensor is the 1:1 Zn2+ complex with bipyridyl ligand 49 which 
is substituted with two BODIPY moieties. This system was found to be highly sensitive to 
phosphate,[51] leading to fluorescence quenching. 
1.5.1.3 Sensors of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
ROS and RNS include diverse species such as peroxynitrite (ONOO－), peroxyl radical 
(ROO•), superoxide radical anion (O 2
• − ), hydroperoxyl (HOO•), and nitric oxide (NO) and 
molecules that readily give rise to radical species, such as  hypocholrous acid (HOCl), 
hydrogen peroxide (H2O2) and nitroxyl (HNO). ROS are natural byproducts of the normal 
metabolism of oxygen.[52, 53] Notably, these species play crucial roles in cell signaling and 
homeostasis.[53, 54] ROS level has close relevance with cell metabolism, which has been well 
documented.[52] Hence, the detection of ROS is of great importance. Fluorescence detection is 
a simple and effective protocol, and in general fluorescent ROS/RNS indicators are 
dosimeters due to the irreversible reaction between probes and ROS/RNS species.  
In 2009, Sekiya reported a novel luciferin-based BODIPY probe 50 (Figure 1-12) for the 
	   19	  
detection of reactive oxygen species.[55] The chemiluminescent probe was oxidized by ROS 
and exhibit emission at 545 nm under neutral pH. Among the various ROSs tested, the 
BODIPY analogue 50 displayed the highest relative chemiluminescence intensity (RCI) in the 
presence of O 2
• − . 
 BODIPY dye 51 is another example of a ROS sensor. This fluorophore is capable of 
detecting hypochlorite (OCl － ) anion on the basis of a specific reaction with p-
methoxyphenol.[56] Upon formation of benzoquinone, the HOMO energy level of the meso-
substituents is lowered, which prohibits the PET process and as a consequence fluorescence is 
restored. The probe was observed to successfully detect the formation of HOCl in an 
enzymatic system and in living macrophage cells upon stimulation.  
Last but not least, Andrew et. al. reported a BODIPY based peroxide probe that has redox 
active quinone units appended at the meso-position.[57] The conversion of hydroquinone units 
to quinone products resulted in the observation of intense fluorescence, especially with a 
phenylene spacer 52.  
 
Figure 1-12 Structures of some BODIPY-based ROS sensors. 
RNS, like ROS, are signaling molecules required for normal cellular functions.[58] 
Peroxynitrite is a short-lived ROS and RNS, formed in vivo from nitric oxide and superoxide 
in a 1:1 ratio. Yang’s group developed a novel BODIPY dye 53[59] that was highly sensitive 
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and selective for the detection of peroxynitrite based on a PET mechanism. A specific 
reaction occurs between peroxynitrite and phenoxyphenyl-derived ketone on nonfluorescent 
probe 53, which forms a highly fluorescent BODIPY derivative. Furthermore the probe was 
proved to successfully detect perxoynitrite generated in murine macrophage cells activated by 
phorbol 12-myristate 13-acetate, interferon-γ and lipopolysaccharide.   
 
Figure 1-13 Structures of BODIPY-based nitric oxide and nitrite sensors 
Nitric oxide (NO), as a typical RNS/ROS second messenger, is involved in the regulation 
of numerous physiological and biological processes.[60] However, in situ detection of NO 
radicals has been greatly limited due to the short life and low physiological concentrations of 
NO radicals. The most common strategy for fluorescent NO sensing is to employ o-
phenylenediamine, a NO-responsive motif.[61, 62d]   Compound 54[62a] is BODIPY-derived NO 
probe. Upon reaction with nitric oxide in the presence of oxygen, the BODIPY dye 54 (Φ = 
0.002) exhibited great enhancement in quantum yield (Φ = 0.74) with the formation of the 
corresponding benzotriazole, which can be explained by the reductive PET mechanism. 
Several other groups have reported additional BODIPY probes for NO.[62b-d] 
        Another kind of RNS species, nitrites, plays a pivotal role in environmental, food, 
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industrial and physiological systems.[63] Due to the importance of nitrites, there has been 
significant interest in trace nitrite determination in recent years. Li et. al.[64] prepared 
BODIPY reagent 56, 1,3,5,7-tetramethyl-8-(4’-aminophenyl)-4,4-difluoro-4-bora-3a,4a-
diaza-s-indacence (TMABODIPY) to determine trace nitrite.  Upon the irreversible reaction 
of nitrite with TMABODIPY first in acidic solution and then in alkaline solution, BODIPY 
diazonate derivative 57 was formed as a stable and extremely fluorescent product (Figure 1-
13). 
1.5.1.4 pH sensors 
       Numerous research has been focused on the design and construction of pH indicators 
inside living cells due to the importance of intracellular pH.[65, 67a] It is worth noting that most 
valuable probes are responsive to near-neutral, cytosolic pH around 6.8-7.4.[66] 
To date, no functional BODIPY-derived probes for cytosolic conditions have been shown, 
however, various BODIPY-based fluorescent sensors for pH detection in organic, aqueous, 
and mixed media have been reported.[67] Figure 1-14 shows the structures of some BODIPY-
based pH sensor. Baruah’s group reported seven BODIPY dyes 58[67d] bearing phenolic or 
naphtholic subunits with pKa values between 7.5 and 9.3. In aqueous solution, compounds 58 
a-c and e-f were demonstrated as fluorescent pH probes whose fluorescence emission and 
excitation intensities are enhanced upon decrease of pH. Further study was not feasible to 
compound 58d owing to its poor solubility in aqueous solution. 
Sensors that are sensitive to more acidic or more basic biological environments such as 
lysosomes have also been under development. Lysosomes, distinct from other cellular 
organelles, have a low pH (5.0–6.0). Thus, lysosomal labeling should be activated only in 
acidic conditions while remain nonfluorescent in neutral conditions, or vice versa. Branchaud 
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and co-workers described BODIPY-based, pH-activated probes 60 with pKa values ranging 
from 3.2 to 5.2.[68a] These pH probes displayed intense fluorescence at pH 4, and the 
fluorescence intensity is reduced at neutral pH. At pH over 7, the fluorescence of these pH 
probes was completely quenched. The dyes can be used for selective lysosome labeling as 
well as in monitoring lysosomal pH changes during physiological and pathological processes. 
Similarly, compounds 61 were designed as pH-responsive fluorescent probes for selective 
imaging of cancer cells in vivo.[68b] 
 
Figure 1-14 Structures of some BODIPY pH sensors 
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1.5.1.5 Indicators for biomolecules 
BODIPY based sensors for biomolecles are relatively rare, however, some BODIPY 
analogues have been developed for the detection and quantification of biomolecules such as 
monosaccharides,[69] thiols,[70] proteins[71] and peptides[72]. 
Boronic acid and esters have been shown as important functional groups in the design of 
carbohydrate sensors.[69] Lakowicz et. al. synthesized monosaccharide indicator 62 (Figure 1-
15), a BODIPY type dye functionalized with a boronic acid group.[69a] In the presence of 
monosaccharides (D-fructose, D-galactose and D-glucose), the BODIPY sensor exhibits 
changes in both absorption and emission spectra. Compound 63 shows a 24-fold fluorescence 
enhancement upon recognition of D-fructose.[69b] This dye was found to be highly selective 
for D-fructose among 24 saccharides.  
Molecules that contain thiols, such as cysteine (Cys), glutathione (GSH), and 
homocysteine (Hcy), are related to a variety of biological processes such as redox 
homeostasis and metal ion binding.[73] Most thiol-sensors contain 2,4-dinitrobenzenesulfonyl 
(DBS) group, an established quencher in the design of thiol sensor. Compound 64[70a] is a 
selective thiophenol probe, associated with a color change from red to yellow and 63-fold 
enhancement in fluorescence upon reaction with thiols. This sensor has also been shown to be 
useful in imaging and discriminating thiols in living cells. Other BODIPY containing 2,4-
dinitrobenzenesulfonyl group as aliphatic thiols sensors have also been reported.[70b-d] 
BODIPY dye 65 was developed as an imaging probe for site-specific labeling of peptides 
that contain two pairs of Arg-Cys in living cells.[71] Upon covalent coupling to peptides, a 
large spectral shift in emission can be observed due to disruption of the conjugation system. 
BODIPY 66 was a site-specific probe designed for labeling and imaging of β-amyloid (Aβ) 
aggregates in brain tissues.[72e] This fluorophore displayed a high affinity for synthetic Aβ 
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aggregates in in vitro binding experiments.  
 
Figure 1-15 Structures of BODIPY biomolecule sensors 
1.5.2 BODIPY dye conjugates and their applications 
Recent years have witnessed a considerable and constant increase in visualization and 
investigation of interactions between proteins, enzymes, oligonucleotides, as well as other 
biomolecules in living cells. Fluorescent labeling has proved to be a powerful tool for in vitro 
detection of these interactions.   
BODIPY dyes possess excellent optical and chemical properties and low toxicities,[74] 
making them one of the most promising candidates as fluorescent probes and labels. Thus, 
diverse BODIPY-based fluorescent labels have been prepared to target at peptide,[75] 
proteins,[76] nucleotides,[77] oligonucleotides,[78] fatty acids,[79] phospholipids,[80] 
polysaccharides,[81] dextrans,[82] receptor ligands[83] and small molecule drugs[84]. Some 
BODIPY dye conjugates are described hereafter. 
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1.5.2.1 BODIPY peptide, protein conjugates 
Fluorescently labelled peptides and proteins can be used to locate the receptors in cells, to 
quantify receptors, or to determine the receptor’s affinity with ligands. Due to the excellent 
physicochemical properties and low toxicities,[74] a few BODIPY dyes have been conjugated 
with peptides[75] and proteins[76]. This is well demonstrated by the BODIPY conjugated 
pepstatin A 67 as a cathepsin D probe (Figure 1-16). Pepstatin A is well known as an inhibitor 
of cathepsin A. As the pepstatin A was tagged with BODIPY, the binding property of 
fluorescent pepstatin A to cathepsin D can be readily characterized by fluorescent polarization 
measurement. 
 
Figure 1-16 Structure of BODIPY conjugates with peptides and proteins  
BODIPY-pepstatin A was also used in fixed cells and live cells as a tool for the study of 
the secretion and trafficking of cathepsin D.[75b] Meijler and colleagues also reported labeling 
of ‘quorum sensing’ (QS) receptors by BODIPY (as in 68) in live cell to investigate the roles 
of QS receptors in cell-to-cell communication.[76b] In their approach the conjugation of 
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BODIPY to protein was realized through a two-step bio-orthogonal labeling strategy in which 
aniline was used to catalyze the oxime formation reaction between the receptor and BODIPY 
dye. 
1.5.2.2 BODIPY Nucleotide and Oligonucleotide Conjugates 
BODIPY as a small fluorophore exhibits a minimal effect on mobility in 
electrophoresis.[12] Thus BODIPY oligonucleotide conjugates can be used in DNA 
sequencing.[78a-c] BODIPY dye-labeled oligomucleotide primers have better photostability 
than fluorescein-labeled primers, which makes the labeled DNA more detectable in 
sequencing gels.[12] Additionally, BODIPY labeled single DNA strands can be used in 
monitoring protein synthesis by using total internal fluorescence microscopy.[78d] 
 
Scheme 1-6. Principle of fluorescence-based detection of the diadenosine triphosphate hydrolase activity of Fhit 
using BODIPY GTP-γ-S thioester (G22183) as a substrate analog. 
	   27	  
BODIPY conjugates of nucleotides can be used as structural probes of nucleotide-binding 
proteins,[12] enzyme substrates[77c] and tools to detect DNA damage.[77d] Invitrogen prepared 
BODIPY® FL GTP-γ-S thioester by linking BODIPY to GTP-γ-S (as in Scheme 1-6). The 
fluorescence of the fluorescent nucleotide is quenched by the PET effect, while it can be 
restored upon binding to G-proteins. Besides, the BODIPY FL GTP-γ-S thioester is an 
important enzyme substrate for Fhit, a member of the histidine triad superfamily of 
nucleotide-binding proteins. Thus, BODIPY nucleotides are useful for imaging and screening 
the activities of Fhit inhibitors and activators (Scheme 1-6). [12]  
1.5.2.3 BODIPY lipids and other conjugates 
Numerous BODIPY dye conjugates of phospholipids, drug analogs, toxins and other 
biomolecules (Figure 1-17) have been synthesized and applied for biological researches.  
 
Figure 1-17 Structures of BODIPY conjugates of phospholipids, Vitamin E and drugs 
BODIPY phospholipids are helpful in studying cell membrane structures and properties 
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such as lipid diffusion,[80a] compartmentalization of specific lipid classes in fungi and 
parasites,[80b] and the activity of lipids in cells.[80c] Mono- and dipalmitoyl-
phosphatidylethanolamine probes 69, both labeled in the hydrophilic head by BODIPY, were 
utilized to study affinity of phospholipids in various lipid bilayer systems.[80d]  
Through labeling of specific drugs, it is possible to study their in vitro and in vivo 
activities, such as affinities to proteins and delivery processes. Atkinson’s laboratory 
synthesized three fluorescent analogues of α-tocopherol incorporating BODIPY fluorophore 
70. These analogues all bind specifically and reversibly to α-tocopherol transfer protein (α-
TTP) with high affinity and thus can serve as fluorescent probes in the study of localization 
and intracellular transport of vitamin E.[84b] Another BODIPY conjugate with wortmannin 71 
was prepared by Cimprich and co-workers as a cell-permeable probe to study kinases in 
cells.[84d] 
1.6 Activated BODIPY fluorophores for labeling  
In the last two decades, various fluorophores have been synthesized with different 
functional groups to generate fluorescent conjugates with proteins, nucleotides, dextrans as 
well as some phospholipids. Two major classes of activated BODIPY fluorophores are 
commonly used in labeling, amine- and thiol-reactive BODIPY.[12] 
1.6.1 Amine-reactive BODIPY 
 These amine-reactive fluorophores incorporate functional groups such as succinimidyl 
esters, sulfonyl chlorides and isothiocyanates that react readily with amines (Scheme1-7).   
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Scheme 1-7 Amine reactive fluorophores: a) succinimidyl esters; b) fluorescent dye sulfonyl chlorides; c) 
fluorescent dye isothiocyanates. 
To date, succinimidyl ester derived BODIPY dyes are the most commonly used amine 
reactive BODIPY fluorophores. Succinimidyl esters are generally stable if kept desiccated, 
and upon reaction with amines, stable amide bonds are formed. Sulfonyl chlorides are 
reactive but the corresponding conjugates are much less stable than amides. Isothiocyanates 
are stable reagents in solution and form reasonably stable thioureas upon reaction with amines.  
Invitrogen supplies a selection of amine-reactive BODIPY dyes. These include 
succinimidyl esters of several BODIPY propionic and pentanoic acids (Figure 1-4). BODIPY 
sulfonyl chlorides and isothiocyanates are not commercially available yet, however, recent 
research has demonstrated the synthesis of isothiocyanate BODIPY derivatives. Ziessel and 
co-workers[85] prepared BODIPY dyes 72 (Figure 1-18) substituted with isocyanato- or 
isothiocyanato group on  phenyl that is derived at the meso-position. The utility of these 
analogues in labeling remains to be explored.  
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Figure 1-18 Structure of isocyanate, isothisocyanate BODIPY analogs 
1.6.2 Thiol-reactive BODIPY 
        Thiol-reactive reagents are mainly based on the iodoacetamides, malemides, benzylic 
halides and bromomethylketones, which generate stable thioether products upon reaction by 
alkylation of thiols. 
a) Iodoacetamides  
Iodoacetamides readily react with all thiols found in peptides, proteins and thiolated 
polynucleotides and form corresponding thioethers.[12]  
The iodoacetamide dyes BODIPY TMR cadaverine IA 73 and BODIPY Fl C1-IA 74 
(Figure 1-19) were developed by Wiktorowicz’s group as fluorescent labeling reagents 
targeting cysteine residues. These dyes show high specificity for cysteine, while little or no 
non-specific labeling can be observed at very low thiol : dye ratios.[86] Besides, the influences 
of these dyes on isoelectric points (pIs) of standard proteins are minimal. The covalent 
linkages formed from these reagents were also shown to be compatible with commonly 
available imaging equipment and in-gel digestion identification by peptide mass 
fingerprinting.[86]    
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Figure 1-19 Structures of iodoacetamides BODIPY derivatives 
b) Maleimides 
Maleimides react with thiol through a 1,4-addition to generate thioethers. The fluorescent 
and chromophoric analogs of N-ethylmaleimide (NEM) are applied similarly as 
iodoacetamides except the reactions with methionine, histidine or tyrosine. A higher pH is 
required for the reaction of maleimides with amines than with thiols.[12]    
 
Figure 1-20 Structures of maleimides BODIPY derivatives 
To date, examples of BODIPY maleimide derivatives have been limited. Nagano’s group 
reported ortho-, meta- and para-substituted maleimide derivatives of BODIPY 75 analogs 
(Figure 1-20). Due to the donor-excited photo-induced electron transfer (d-PET) effect from 
BODIPY to maleimide, the fluorescence of ortho-substituted maleimide BODIPY derivatives 
was strongly quenched. It was observed that the fluorescence intensity was enhanced by 350-
fold upon the formation of thioethers. Probe 75a was applicable to label proteins of extremely 
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low concentrations in gels.[87]     
1.6.3 Other Functional BODIPY derivatives  
The amine- and thio- reactive BODIPYs have been widely used to label purified 
biomolecules. These reagents have also found utility in non-selective in situ labeling of total 
cellular thiol or amine content.[12] There exists a need for bio-orthogonal in situ labeling that 
can be carried out under mild conditions with high degrees of selectivity. 
The copper-catalyzed azide-alkyne cyloaddition, or the “Click” chemistry, is one of the 
most widely used bioorthogonal labeling reactions.[12] Wang and co-workers recently 
reported[88] the synthesis of a new type of BODIPY compound 76 that carries an azido group 
at the 3-position of the BODIPY core (Figure 1-21). The azido group quenches the 
fluorescence of the dye, however, the fluorescence is switched on upon reaction with alkynes 
to afford the corresponding triazole derivatives. In another report, monofunctional BODIPY 
dyes containing an azide 77a and alkyne 77b were prepared as pH sensors.[89] These 
analogues could potentially be used as bio-orthogonal probes.  
 
Figure 1-21 Structures of azido, alkynyl BODIPY derivatives 
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1.7 General perspectives and objectives 
1.7.1 Stability of BODIPY in acidic and basic condition  
Many BODIPY fluorophores possess high molar extinction coefficients and are highly 
fluorescent.[10, 11, 90] In addition, many BODIPY fluorophores have been reported to be 
relatively insensitive to changes in pH and polarity, and are more photochemically stable than 
many other commercially available fluorophores.[10, 11]  
Although some reactivities of BODIPY have been documented in the literature,[10, 11]  
detailed studies on the stability of BODIPY have been rare.[91] One recent publication relates 
to the replacement of the fluorine atoms in BODIPY by hydroxyl in the presence of a strong 
Lewis acid such as aluminium chloride.[29] In another report, it was shown that BODIPY 
analogues could be converted to their corresponding dipyrrins when treated with potassium 
butoxide under microwave conditions.[92] It is noted that BODIPY has been given credit in 
numerous articles to be chemically stable, however, according to the observations made in our 
laboratory, BODIPY fluorophore partially degraded when it was incorporated into 
oligonucleotides by the phosphoramidite chemistry-based solid-phase synthesis, particularly 
during acid and base treatments.[93] Thus, the relative stability of various BODIPY analogues 
in acidic and basic conditions were compared in order to facilitate the selection of suitable 
BODIPY analogues for nucleic acid labeling via the phosphoramidite chemistry based solid 
phase synthesis approach.  
1.7.2 Synthesis of the functional BODIPY derivatives 
As mentioned above, various functional fluorophores can be introduced to different 
molecules. While BODIPY based fluorophores recently show an ever-growing success in 
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applications in fluorescent switches, and fluorophores in sensors and labels, it is worthwhile 
to expand the availability of activated BODIPY fluorophores for labeling target molecules. 
Herein we aim at the synthesis of azido- and isothiocyanate BODIPY derivatives. The latter 
will be transformed from the corresponding azido BODIPY. 
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Chapter 2 Synthesis of peptide nucleic acid 
2.1 Peptide nucleic acid (PNA) – an artificial nucleic acid 
DNA and RNA are carriers of genetic information. For the past 2-3 decades, there has 
been an increasing interest in the discovery and development of nucleic acid-based 
approaches for diagnosis and therapy.[94] In approaches such as antisense and RNA 
interference, some common features are required for the successful application of these 
nucleic acid-based therapies. Among these requirements, the therapeutic nucleic acids must 
bind to their target sequence with a desired affinity in a highly selective fashion. These 
molecules must also possess suitable stabilities, both chemically and enzymatically, so that 
they can reach their target sites before significant degradation takes place.  
 
Figure 2-1 Native nucleic acids–DNA, RNA and PNA with N-(2-amino-ethyl)-glycine backbone 
Peptide nucleic acid (PNA, Figure 2-1) meets all these requirements. PNA is designed as 
nuclease resistant DNA-binding ligands that can form stable and highly sequence-specific 
	   36	  
complexes with DNA.[95] As a DNA mimic, PNA is structurally similar to DNA. Natural 
oligonucleotides, both DNA and RNA, have backbones with sugar-phosphate units while 
PNAs are built upon a pseudopeptide chain constituted by N-(2-aminoethyl)glycine 
monomers linked with the four nucleobases via methylene carbonyl bonds.  
PNAs were first independently synthesized during the 1980s in Prof. Ole Buchardt’s 
laboratories together with biochemist Peter Nielsen.[96] PNA is regarded as a fully synthetic 
DNA/RNA-binding ligand with a neutral achiral peptide-like backbone. 
The pseudopeptide backbone confers PNAs with superior chemical and enzymatic 
stability. PNAs are resistant to enzymatic cleavage and thus not expected to degrade inside 
living systems.[97] On the other hand, PNA is capable of recognizing complementary DNA 
and RNA sequences to form stable duplex structures through Watson-Crick base pairing.[98] 
The hydrogen bonding and the hybrid complexes exhibit extraordinary thermal stability and 
unique ionic strength effects.  
PNAs have been widely applied in molecular biology and biotechnology as useful tools 
in genetic diagnostics and specific regulations of gene expression.[99] They also have been 
extensively investigated as potential antiviral and anticancer drugs as well as antigene and 
antisense therapeutic agents.[97,99, 100]  
2.2 PNA chemistry 
PNA can be prepared in ways analogous to peptides, which involves coupling the 
carboxyl to the amino groups. Similarly, both solid and solution phase synthetic approaches 
can be utilized for PNA synthesis. In both approaches suitable protecting group strategies are 
crucial towards the synthesis of PNA monomers and subsequent oligomerization.  
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2.2.1 Amino-protecting groups 
The α-amino group requires temporary protection in PNA chemistry. Some commonly 
used amino protecting groups are described below. 
2.2.1.1 tert-Butoxycarbonyl (Boc)  
The Boc protecting group can be readily removed upon treatment with strong acids such 
as trifluoroacetic acid, either neat or in dichloromethane, or with hydrogen chloride in 
methanol. 
2.2.1.2 Fluorenylmethyloxycarbonyl (Fmoc)  
The 9-fluorenylmethyloxycarbonyl (Fmoc) group is an alternative to the Boc group. The 
Fmoc protecting group can be deprotected by treatment with bases such as piperidine. The 
elimination product fulvene from the deprotection can often be trapped by a nucleophile such 
as thiol.   
2.2.1.3 Benzyloxy-carbonyl (Z) group 
Z Group is a widely used protecting group for amines because of its high stability in base and 
mild acid treatments and the versatile removal conditions. The Z protecting group can be 
removed by treatment of catalytic hydrogenolysis.[101]  
2.2.2 Carboxyl protecting group 
Protecting groups for carboxyls must be compatible with those for amino groups and any 
other protecting groups on nucleobase residues. Some commonly used carboxyl protecting 
groups are summarized below.  
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2.2.2.1 tert-Butyl (tBu) ester 
tert-Butyl (tBu) group can be used as carboxylic acid protecting group in both solution and 
solid-phase synthesis of PNA. tert-Butyl esters are deprotected under the same conditions as 
Boc, i.e. by treatment with trifluoroacetic acid.  
2.2.2.2 Benzyl (Bn) ester 
Benzyl is one of the commonly used carboxylic acid protecting groups. The benzyl group can 
be cleaved by hydrogenation.  
2.2.2.3 Allyl (All) group 
The allyl (all) group can be used as an alternative for carboxylic acid protection. It can be 
readily removed by treatment with a catalytic amount of Pd(0), such as 
tetrakis(triphenylphosphine)palladium(0), in the presence of an appropriate nucleophile. The 
latter is used to trap the allyl palladium complex. 
2.2.2.4 Methyl (Me) and ethyl (Et) ester 
These simple esters can be cleaved by saponification, usually by treatment with lithium 
hydroxide or sodium hydroxide in methanol. 
2.2.3 Coupling methods 
The carboxy group on the PNA backbone is usually activated in the coupling step. The 
carboxyls can be either activated in situ, or prepared as the corresponding activated esters 
such as pentafluorophenyl esters.  
2.2.3.1 Carbodiimides 
In peptide bond formation, activated carboxylic acid derivatives are rarely stable. Thus 
the protected precursors are normally activated for coupling in situ. Carbodiimides such as 
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dicyclohexylcarbodiimide (DCC) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
are most commonly used as activating agents in these coupling reactions. EDC is used as an 
alternative to DCC because the by-product can be readily removed by extraction with water.  
2.2.3.2 N-Hydroxy succinimide and triazole-based reagents 
The O-isourea intermediates generated by treatment of carboxyls with carbodiimides are 
unstable and are often further treated with N-hydroxy succinimide and triazole analogues such 
as 1-hydroxy-benzotriazole (HOBt) and 1-hydroxy-7-aza-benzotriazole (HOAt). This 
treatment transforms the O-isourea intermediate into a less reactive, but more stable, reactive 
intermediate for peptide formation reactions. Benzotriazol-1-yl-oxy-
tris(dimethylamino)phosphonium hexafluorophosphate (BOP) has also been used in this 
respect due to its stability and solubility, however the by-product hexamethylphosphoric acid 
triamide generated from BOP is carcinogenic. 
2.2.4 Synthesis of PNA monomer 
As previously described, a PNA monomer consists of (2-aminoethyl)glycine backbone 
with a nucleobase attached. Two main routes have been used towards the synthesis of the 
backbone unit (Scheme 2-1). It is reported that the desired peptide backbone 82 can be 
obtained in high yields via either reductive amination of a glycine ester 79 with a suitably N-
protected aminoacetaldehyde 78,[102]  or alkylation of mono-N-protected ethylenediamine 80 
with a bromoacetic acid ester 81.[103] 
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Scheme 2-1 Synthesis of protected (2-aminoethyl) glycine. Reagents and conditions: i) NaBH3CN, MeOH; ii) 
K2CO3, CHCl3/CH3CN 
Suitably protected nucleobases 83 can then be attached to the PNA backbone via amide 
bond formation activated by coupling agents such as DCC,[104] EDC[105] and BOP[105, 106]   
(Scheme 2-2). 
 
Scheme 2-2 Synthesis of PNA monomer. Reagents and conditions: i) DCC/EDC/BOP, DMF. PG: protected 
group.  
Many PNA monomers are commercially available, however, they are very expensive. 
Commercial PNA monomers are also limited in variety. Some unusual or modified N-(2-
aminoethyl)glycine derivatives have been developed. Hudson and co-workers[107] reported a 
convenient and scalable synthesis of N-(2-N-Boc-aminoethyl)glycinate based on the reductive 
amination of N-Boc-ethylenediamine with ethyl glyoxylate hydrate. The novel strategy took 
advantage of ethyl glyoxylate hydrate instead of traditional aldehyde to generate the desired 
backbone in virtually quantitative yield and high purity. Ugi reaction has also been shown for 
the synthesis of PNA monomers (Scheme 2-3).[108] Thus, PNA monomers 89 were prepared 
by treating nucleobase acetic acids 86 with primary amines 85, oxo-components 87 and N-
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mono protected ethylenediamine derived mono isocyanides 88, in a four component fashion. 
Xu et. al. utilized this method to obtain not only PNA monomers but also PNA chain 
elongation products.[108d] 
 
Scheme 2-3 One-pot synthesis of PNA monomer via the four component Ugi reaction. 
2.2.5 Synthesis of PNA oligomers 
PNA oligomers can be prepared through either solid or solution phase synthesis. The 
solid phase synthesis has become the preferred method, especially for small-scale 
preparations, due to the simplicity in this approach compared with solution phase synthesis. 
Solid phase synthesis of PNA is rather similar to that of peptides, which can be carried 
out either from the C to N or N to C termini. The synthesis cycle involves the following steps: 
1) chain elongation (coupling), 2) washing, 3) removal of the transient protecting group and 4) 
washing.[109] 
Functionalized polystyrene is among the most commonly used solid support. N-Protected 
amino acid (e.g. glycine) is attached to the solid support via the C-terminus to a cleavable 
linker. The choice of linker is highly relevant to the protecting group strategy used. For 
instance, the Wang resin, 4-(hydroxylmethyl)phenol, is applicable to the Fmoc/ 
benzhydryloxycarbonyl (Bhoc) chemistry. The final product can be cleaved from the resin by 
the treatment with acid such as TFA. While HMBA (4-(hydroxymethyl)benzoic acid linker) 
linker is relatively more stable under acidic condition so that it can be used for 
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monomethoxytrityl (MMT)/Acyl chemistry.  
2.3 Comparison of PNA with DNA and RNA 
Compared with DNA and RNA, PNA exhibits a better chemo-stability due to the 
polyamide-based backbone. The amide bond is stable under acidic and basic conditions. Thus 
PNA shows great stability over a wide pH range. PNA is resistant to degradation by enzymes 
such as nucleases, proteases or peptidases.   
PNA binds complementary DNAs with affinity that is often higher than DNA duplexes, 
partially due to the neutral PNA backbone that reduces the electrostatic repulsion between 
phosphate negative charges. PNA/PNA duplexes are stable. Unlike DNA duplexes, 
PNA/PNA duplexes are not affected by the ionic strength of the media. PNA/DNA duplexes 
show greater specificity compared with DNA duplexes. As such, PNAs are very useful in 
discriminating single base mismatches.    
On the other hand, the neutral backbone also leads to low water solubility of PNA. PNA 
has a tendency to aggregate, which is also attributed to the neutral amide backbone. The 
degree of aggregation is sequence dependent.[96] The low solubility of PNA can be mitigated 
to some extend by the addition of solubility enhancers.[110] PNA solubility also depends on 
purine/pyrimidine base ratio and the size of PNA oligomer.[111] Much like DNAs, PNAs have 
rather poor cellular permeability, which limits its efficiency in applications such as antigene 
or antisense therapies.[112]  
2.4 Applications of PNA  
Due to its unique properties, PNA has been explored for its potential in applications such 
as antisense and antigen therapeutics, molecular biology tools and diagnostics. 
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2.4.1 Antigene and antisense therapeutic agents 
        The potential in sequence-specific modulation of gene expression makes PNA a 
promising candidate as antisense and antigen therapeutic agent. In principle, several strategies 
were applied to design PNA based gene therapeutic drugs, including transcription arrest 
(antigen strategy),[113] translation arrest (antisense strategy),[114] and inhibition of 
replication.[115] 
Transcription arrest can be achieved through the formation of a stable triplex, a strand-
invasion or a strand displacement complex with DNA. Under transcription arrest, RNA 
polymerase is inhibited due to the hindrance from the PNA/(DNA)2 triplex. One of the major 
obstacles for its in vivo application as antigen agents is that PNA strand invasion is dependent 
on salt conditions. Under moderate salt concentration, PNA strand invasion occurs at a very 
low rate.[100b]  
 In the antisense approach, binding of oligonucleotides to messenger RNA leads to 
translational arrest.[116] PNA shows tighter and more specific binding to RNA compared with 
DNA/RNA duplex. Thus PNA is regarded as an excellent candidate in antisense drug 
development. Nielsen’s group showed that C-rich (C4T4CT4) and T-rich PNAs (TC6T4CT) 
specifically arrest type 1 human immunodeficiency virus in vitro.[114b]   
2.4.2 PNA probes in diagnosis and detection 
PNA binds to nucleic acids with specificity higher than DNA, sensitivity and accuracy, 
and have thus been considered as an extraordinary candidate for various genetic diagnostic 
techniques. For instance, the PNA-based fluorescence in situ hybridization (FISH) technique 
has provided an attractive alternative for application in quantitative analysis of telomere 
length, chromosome painting and bacterial identification.[117] Additionally, PNA-mediated 
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PCR clamping technique is favored for identification of genetic diseases.[118] Furthermore, 
PNA has been exploited in applications such as molecular beacons.[119]  
2.4.3 PNA as tools in molecular biology and functional genomics 
PNA also has exhibited potentials for use as tools in molecular biology and functional 
genomics. 
PNA in combination with methylases and restriction endonucleases can be used to cleave 
DNA in a site-specific manner. This method could mitigate the problem of DNA cleavages at 
more than one site when restriction enzymes are used alone. In this approach, the PNA target 
site overlaps with the methylation/restriction enzyme site and prevent methylation of DNA by 
methylases, where unbound DNA sequences are methylated. Upon PNA-DNA dissociation, 
cleavages by restriction enzymes at a single site can be effected.[96, 120]  
PNA is also very useful in the purification of nucleic acids. For instance, it was shown 
that target nucleic acid can be purified by PNA linked to His-tag that is immobilized on nickel 
affinity columns.[120] 
In conclusion, due to its extraordinary properties, PNA has found a wide range of 
applications and is considered an excellent candidate in therapeutic applications.   
2.5 General perspectives and objectives 
PNA is generally prepared by the coupling reaction between amino and carboxyl groups. 
This approach is versatile, however, can give rise to products in low yields, especially for 
guanylate PNA analogues.    
The Staudinger ligation was shown to be a useful method to couple a peptide with a C-
terminal phosphinothioester to another peptide with an N-terminal alpha-azido group in a 
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number of publications.[121, 122] Work described in this thesis attempted to explore the utility 
of this reaction in the preparation of short PNA sequences, and in the long term ligation of 
oligomers.  
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Chapter 3 Results and Discussion 
Synthesis of BODIPY analogues 
3.1 Overview of stability test of BODIPY in acidic and basic condition 
Fluorescently labeled oligonucleotides have found a wide range of applications.[123]	  
Towards this end, our group successfully prepared BODIPY phosphoramidites and then 
incorporated them into oligonucleotides by the phosphoramidite-chemistry based solid-phase 
synthesis.[124]	  In	  this	  approach,	  degradation of BODIPY derivatives was observed during the 
detritylation and amminolysis steps. This led us to evaluate the stability of BODIPY 
analogues under the conditions under which BODIPY is incorporated into oligonucleotides 
using the phosphoramidite chemistry. 
4,4-Difluoro-4-bora-1,3,5,7-tetramethyl-2,6-diethyl-8-methyl-3a,4a-diaza-s-indacene 91 
was chosen as a model for the stability experiments, as the subsitutents on the dipyrromethene 
ring are necessary to avoid potential reactions at these sites. This compound was readily 
prepared using a literature procedure by the treatment of 2,4-dimethyl-3-ethylpyrrole 90 with 
acetyl chloride 91, followed by complexation with boron trifluoride diethyl etherate in the 
presence of triethylamine.[125] In addition, three other analogues, i.e. 4,4-dimethyl 93,[126] 4,4-
dimethoxy 94[127] and 4,4-diphenyl 95[128] BODIPY were prepared according to methods 
documented in the literature (Scheme 3-1). 
	   47	  
 
Scheme 3-1. Reagents and conditions: i). CH2Cl2, reflux, 3 h; ii). CH2Cl2, NEt3, BF3•Et2O, reflux; iii). MeMgBr, 
CH2Cl2, 0 oC; iv). NaOMe, MeOH, CH2Cl2, reflux; v). PhMgBr, CH2Cl2, 0 oC. 
3.1.1 Stability tests of BODIPY analogues in the presence of acid and base 
3.1.1.1 Stability under acidic conditions 
The stability of BODIPY fluorophores 92-95 in acidic solutions at room temperature was 
followed by recording 11B NMR spectra at appropriate intervals. A sealed capillary insert of a 
solution of sodium tetraphenylborate in D2O was used as an internal standard. In the case of 
an unstable substrate, the disappearance of substrate was monitored. In order to eliminate the 
broad 11B resonance signal from the NMR tube, which overlaps with both substrate and 
internal standard signals, a linear prediction method [129] was used to process the 11B NMR 
data. As shown in Figure 3-1, this linear prediction method allows for the suppression of 
background signals from the NMR tube.  
The following processing parameters were used for the linear backward prediction algorithm:  
Lb = 10 Hz 
ME_mod = LPbr 
NCOER = 32 
LPBIN = 1024 
Tdoff = 32 
FCOR = 1 
PKNL = TRUE 
N
H
+
Cl
O
N B N
Y Y
92; Y=F
93; Y=Me
94; Y=OMe
95; Y=Ph
90 91
i, ii
iii
iv
v
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FT_mod = FSC 
 
Figure 3-1 11B NMR spectra of 87 recorded in the presence of an internal stand (NaBPh4). a) Before applying 
the linear backward prediction algorithm, and b) after applying the linear backward prediction algorithm. 
3.1.1.2 Stability under basic conditions 
Stability tests of BODIPY analogues in basic conditions were carried out in the same way 
as described above for acid stability experiments, except that bases were used instead of acids. 
3.1.2 Stability results  
It was found that 4,4-diphenyl BODIPY 95 was stable in a solution of dichloroacetic acid 
(50 mol. equiv.) in dichloromethane, indicated by the fact that no new signals appeared after 3 
d (Figure 3-2a). 4,4-Difluoro BODIPY 92 is less stable under acidic conditions. When 
BODIPY 92 was treated with dichloroacetic acid (50 mol. equiv.) in dichloromethane, 8% 
decomposition was observed after 24 h. Treatment of 4,4-dimethyl BODIPY 93 under the 
same conditions led to complete decomposition in 6 hs to give a single boron-containing 
product, which was not identified (Figure 3-2b). 
	   49	  
 
	   50	  
 
Figure 3-2 (a) 95 in 50 molar equivalents dichloroacetic acid-dichloromethane for 0 time and 3 days, 
respectively; (b) 93 in 50 molar equivalents dichloroacetic acid-dichloromethane for 0 time and 6 hours, 
respectively; (c) 94 in 50 molar equivalents dichloroacetic acid-dichloromethane for 0 time, 1.5 and 12 hours, 
respectively.  
Interestingly, treatment of 4,4-dimethoxy BODIPY 94 with 10 mol. equiv. of 
dichloroacetic acid in dichloromethane led to full conversion of 94 to a single product in 12 h 
(Figure 3-2c). When this reaction was carried out on a preparative scale (Scheme 3-2), the 
product was identified as the corresponding anhydride 96. The identity of this product 96 was 
confirmed by X-ray crystallography (Figure 3-3) 
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Scheme 3-2 Reagents and conditions: i). CH2Cl2, Cl2CHCOOH, r.t. 
 
Figure 3-3 X-Ray crystal structure of 4,4-bis(dichloroacetoxy) BODIPY. 
When a stronger acid, i.e. trichloroacetic acid (50 mol. equiv.), was used, both 4,4-
difluoro 92 and 4,4-diphenyl 95 BODIPY became unstable. Thus, 50% of 4,4-difluoro 
BODIPY 92 undergoes decomposition after incubation in dichloromethane in the presence of 
50 mol. equiv. of trichloroacetic acid for 3 h. Under the same conditions, 50% of 4,4-diphenyl 
BODIPY 95 undergoes decomposition in 4 h. 
Stability of the BODIPY analogues under basic conditions was assessed as follows. The 
substrate was dissolved in tetrahydrofuran followed by addition of aqueous ammonium 
hydroxide and methanol (Methanol was not added in the case of 4,4-dimethoxy BODIPY 94). 
THF and methanol were added in order to solubilize the substrates. Solutions of BODIPY 
analogues were then heated at 55oC in sealed vials. At appropriate time intervals, samples 
were removed and 11B NMR spectra were recorded.  
N B N
MeO OMe
N
B
N
Cl2HCOCO OCOCHCl2
i
94 96
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Figure 3-4 BODIPY 94 in dichloroacetic acid (50 mol. equiv.)–dichloromethane for 2 and 8 hs, respectively 
The results showed that 4,4-dimethoxy BODIPY 94 is the least stable under this 
condition. Within about 8 h, half of the starting materials degraded, forming a product with a 
11B shift of 1.2 ppm (Figure 3-4). Under this condition 4,4-dimethyl 93 and 4,4-difluoro 
BODIPYs 92 are stable for up to 8 h, 4,4-diphenyl BODIPY 95 is stable for 7 days. 
3.1.3 Conclusions 
From the results obtained in this study, 4,4-diphenyl substituted BODIPY 95 appears to 
be the most stable under both acidic and basic conditions. It is also noted that substitution of 
the fluorine by phenyl does not compromise the fluorescent intensity of the fluorophore (Φ = 
0.91 in dichloromethane for 95 and Φ = 0.83 for 92).[11] The phenyl analogue 95 shows a 
larger Stoke’s shift (35 nm) than the fluoro-BODIPY 92 (21 nm).[11] It is possible that the 4,4-
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diphenyl substituted BODIPY analogues could be more suitable for oligonucleotide labeling 
via the phosphoramidite chemistry-based solid phase synthesis. Work in this direction will be 
explored in our laboratory in the future. 
3.2 Some reactions of a 4,4-bis(dichloroacetoxy)BODIPY mixed anhydride 
During the course of the evaluation of the stability of some BODIPY analogues, it was 
found that when 2,6-diethyl-4,4-dimethoxy-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-
indacene 94 was treated with dichloroacetic acid, the corresponding mixed anhydride 4,4-
bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 96 was 
formed (Scheme 3-2) and isolated in good yield. The synthetic utility of this new BODIPY 
species was explored. 
When the mixed anhydride 4,4-bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-
bora-3a,4a-diaza-s-indacene 96 was treated with simple alcohols alone, such as methanol and 
ethanol, virtually no reaction was observed. However, in the presence of a strong base, such 
as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), rapid formation of 2,6-diethyl-4,4-dimethoxy 
(or 4,4-diethoxy)-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 94 (or 97) was 
observed, and the resulting products can be isolated in good yields (91%) by column 
chromatography (Scheme 3-3). Similar results were observed when phenol was used as a 
substrate in the presence of DBU, resulting in the formation of 2,6-diethyl-4,4-diphenoxy-
1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 98 in 69% yield. If a 1,2-diol is used 
instead of a monofunctional alcohol, a cyclic borate is formed. Thus, treatment of 4,4-
bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 96 
with ethylene glycol and catechol in the presence of DBU gave corresponding cyclic borate 
esters 99 and 100 in 29 and 44% yield, respectively. Interestingly, when 96 was allowed to 
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react with uridine in the presence of DBU in N,N-dimethylformamide (DMF), uridine was 
labeled with BODIPY through the formation of a 2’,3’-cyclic borate ester 101. 
 
Scheme 3-3 Reagents and conditions: i). CH3OH, DBU, CH2Cl2; ii). EtOH, DBU, CH2Cl2; iii). PhOH, DBU, 
CH2Cl2; iv). HOCH2CH2OH, DBU, CH2Cl2; v). catechol, DBU, THF; vi). uridine, DBU, DMF; vii). HNEt2, 
CH2Cl2. 
Surprisingly, when 4,4-bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-
3a,4a-diaza-s-indacene 96 was treated with diethylamine in dichloromethane, 4,4-
bis(dichloroacetoxy)-2,6-diethyl-8-(2-(N,N-diethylamino)ethyl)-1,3,5,7-tetramethyl-4-bora-
3a,4a-diaza-s-indacene 102 was isolated in 41% yield. It was found, however, that this 
reaction was not observed when dichloromethane was replaced with tetrahydrofuran as 
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solvent. This observation clearly suggests the involvement of dichloromethane in the reaction. 
The nature and scope of this chemistry is discussed below. 
In conclusion, 4,4-bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-3a,4a-
diaza-s-indacene 96 as a reactive intermediate can be readily prepared and isolated by column 
chromatography and further used for the preparation of a series of BODIPY derivatives. 
3.3 A Mannich-Type Reaction at the meso-Methyl Position of the BODIPY Fluorophore 
As is described in the previous section, 4,4-bis(dichloroacetoxy)-2,6-diethyl-8-(2-(N,N-
diethylamino)ethyl)-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene 102 was isolated as a 
major product when 4,4-bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-3a,4a-
diaza-s-indacene 96 was treated with diethylamine in dichloromethane.   
It was recognized in the literature that dihalomethanes and secondary amines (and tertiary 
amines) react readily. For instance, triethylamine and dichloromethane react to form N-
chloromethylammonium.[130] Similar reactions were also documented elsewhere.[131] It was 
proposed in the literature[132] that treatment of dichloromethane with dimethylamine gave 
N,N,N′,N′-tetramethylmethylenediamine (Scheme 3-4). This hypothesis was later confirmed 
experimentally.[133] Formation of an iminium salt was subsequent suggested in the 
literature.[133a]  Indeed when 1H NMR of a solution of diethylamine in deuterated 
dichloromethane were recorded over 48 h, formation of a new species was observed (Figure 
3-5).  
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Figure 3-5 Diethylamine in deuterated dichloromethane at 0 and 48 hs, respectively. 
 
Scheme 3-4 Proposed pathway for reactions between secondary amines and dichloromethane.[132] 
When 2,6-diethyl-4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 92 
was subjected to treatment with secondary amines in dihalomethanes 103 (Scheme 3-5), 
Mannich-type reactions were observed. Depending on the steric bulk and basicity of the 
secondary amine, either dichloromethane or dibromomethane can be used in these reactions 
	   57	  
(Table 3-1). In all cases, the Mannich products 103 were readily isolated in moderate to good 
yields (Table 3-1). 
 
Scheme 3-5 Mannich reactions of 4,4-difluoro	  BODIPY with various secondary amines. 
Table 3-1 Mannich reaction (Scheme 3-5) products 
 
a. No product formation was observed by TLC after heating at 40 °C for 3 d. 
These observations are analogous to the Mannich reactions involving secondary amines 
and dihalomethanes that have been documented in the literature.[134] In connection with the 
pathway described in Scheme 3-5, a reaction between 2,6-diethyl-4,4-difluoro-1,3,5,7,8-pen-
tamethyl-4-bora-3a,4a-diaza-s-indacene 92 and N,N,N′,N′-tetraethylmethylenediamine 110 
N B N
F F
N B N
F F
2o amine, CH2X2
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was carried out in THF (Scheme 3-6). As expected, the corresponding Mannich product 104 
was isolated in good yield (93%). 
 
Scheme 3-6 Reagents and conditions: i) THF, 40oC. 
 
Scheme 3-7 A postulated mechanism for the Mannich-type reaction. 
Based on these observations, a reaction mechanism is postulated as follows (Scheme 3-
7). Upon deprotonation of BODIPY, the intermediate reacts with the highly electrophilic 
Mannich base, leading to carbon–carbon bond formation at the BODIPY meso-methyl 
position. 
The UV/vis absorption and fluorescent emission spectra of 104 were recorded in 
acetonitrile and are shown in Figure 3-6. The other Mannich products 104–109 show very 
similar absorption and fluorescent profiles. 
N B N
F F
N B N
F F
N
92 106
N N+ i
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Figure 3-6 Absorption and fluorescence emission spectra (excited at 517 nm) of compound 104 in acetonitrile. 
As can be seen from Figure 3-6, the Mannich product 104, as well as 104–109, shows 
rather typical BODIPY absorption and emission profiles, with small Stokes shifts. All 
products are highly fluorescent, with high fluorescent quantum yields (Table 3-2). 
Table 3-2 UV/vis absorption, fluorescent emission maxima and fluorescent quantum yields of compounds 104-
109 in acetonitrile. 
  Entry λmax abs(nm) λ max em(nm) ε (✕10
4
 cm
-1
mol
-1
) Φ 
a 
104 517 530 7.30 1.0 
105 518 530 6.59 0.80 
106 514 530 6.57 0.90 
107 517 530 7.16 0.86 
108 518 531 7.23 0.85 
109 519 530 7.01 0.75 
aThe fluorescent quantum yields were determined against fluorescein in 0.1 M NaOH, which has a quantum 
yield of 0.95±0.05 when excited at 496 nm.[135] 
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In conclusion, an unprecedented Mannich-type reaction between 2,6-diethyl-4,4-difluoro-
1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 92 and dihalomethane was found to be 
straightforward and gave corresponding meso-modified BODIPY Mannich products in 
moderate to good yields. This Mannich-type reaction can provide ready access to meso-
substituted BODIPY analogues. 
3.4 BODIPY-based fluorescent sensors for ions 
It was shown that 8-methyl BODIPY 92 undergoes a Mannich-type reaction when treated 
with a secondary amine in dihalomethane, allowing for ready access to meso-substituted 
BODIPY. These results prompted us to investigate the utility of this Mannich chemistry in the 
preparation of BODIPY analogues that bear ion binders at the 8-position and to explore their 
applications in ion sensing. 
 
Figure 3-7 Structures of BODIPY based ion sensors. 
Five BODIPY analogues 111-115 bearing substitution at the meso-position were 
synthesized in moderate yields from 2,6-diethyl-4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-
3a,4a-diaza-s-indacene 92 and corresponding secondary amines under the Mannich reaction 
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conditions described in Scheme 3-5. It is noted that the conversion for the 
dihydroxyethylamine and pyridine derivatives were low and most of the unreacted starting 
material was recovered after the reaction was terminated. 
3.4.1 Screening 
Compounds 111-115 were screened at Professor Antai Wu’s laboratory at the National 
Changhua University of Education in Taiwan against a panel of 12 cations (Ca2+, Cd2+, Co2+, 
Cu2+, Hg2+, K+, Li+, Mn2+, Na+, Ni2+, Pb2+ and Zn2+) and 7 anions (F−, Cl−, Br−, I−, HSO4−, 
NO3− and AcO−). Experiments described in 3.4.1-3.4.2 were performed by De-Jhong Liao.  
  
Figure 3-8 UV/vis spectra of 114 and 115 in the presence of various ions. a) UV/vis spectra of 114 recorded in 
DMSO (1.8 × 10-5 M) after addition of 10 equivalents of various anions; b) UV/vis spectra of 115 recorded in 
CH3CN (8 × 10-6 M) after addition of 10 equivalents of various metal ions. 
Among these five receptors, 114 and 115 were found to respond to selected ions and were 
furthered screened as sensor candidates. In the presence of F-, a red shift with a hypochromic 
effect was observed in the UV/vis spectra of receptor 114 (Figure 3-8a) in DMSO, with a 
sharp decrease of absorbance at 527 nm and rising of a new peak at 438 nm. On the other 
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hand, from the UV/vis spectra, it was found that 115  (Figure 3-8b) showed a hypochromic 
effect in the presence of Cu2+ ion in acetonitrile. 
The solution of receptor 114 showed a dramatic color change from pink to virtually 
colorless that could easily be seen with the naked eye (Figure 3-9a). When the solutions were 
irradiated with a UV lamp, the fluorescence difference of 114 can also be easily distinguished 
in the presence of various anions. (Figure 3-9b) 
 
 
Figure 3-9 a) Naked eye detection of 114 upon addition of 10 equiv. of various anions in DMSO (5.6 µM); b) 
fluorescent changes of sensor 114 in DMSO (5.6 µM) after addition of 10 equiv. of anions (irradiated with UV 
lamp). 
The chemosensing properties of receptors 114 and 115 were further investigated by 
fluorescent spectroscopy. Receptor 114 did not exhibit any selective recognition among a 
series of tested metal ions; however, it exhibited a highly selective recognition toward F− in 
the presence of various anions in DMSO (Figure 3-10a), with a sharp decrease in emission at 
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550 nm. F− ions also led to a blue shift (62 nm) in the fluorescent emission spectrum of 114.  
On the other hand, the results indicated that the fluorescence of receptor 115 was strongly 
quenched in the presence of Cu2+ ion in CH3CN (Figure 3-10b), where other metal ions did 
not significantly affect the fluorescence intensity of 115. Thus the observed quenching 
efficiency by Cu2+, which is calculated as (I-I0/I0)×100% at 518 nm, was nearly 95% where 
the other metal ions only caused slight quenching in fluorescent emission intensity.  
     
Figure 3-10 Fluorescence spectra of 114 and 115 upon addition of various ions. a) Fluorescence spectra of 114 
(1.35 × 10-5 M) upon addition of various anions (10 equiv.) in DMSO. λex= 375 nm; b) fluorescence spectra of 
115 (8 × 10-6 M) upon addition of various cations (10 equiv.) in CH3CN. λex= 516 nm. 
The fluorescence titrations of receptors 114 and 115 were performed in the presence of 
varying concentrations of F− or Cu2+, respectively. The fluorescence titration spectra of 114 in 
DMSO also showed decreases in fluorescent emission intensity in a F- concentration-
dependent manner (Figure 3-11a). Based on the fluorescence titration measurements, 
detection limit of receptor 114 for F- was found to be 3.6×10-5 M. The association constant for 
114*F− complex was found to be 3.73×104 according to the Stern-Volmer plot (Figure 3-12a). 
The Job plot showed that receptor 114 formed a 1:1 complex with F−. (Figure  3-12b) 
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Figure 3-11 Fluorescence spectra of 114 and 115 in the present of varying concentrations of ions. a) 
Fluorescence spectra of 114 (7.2×10-6 M) in DMSO upon addition of increasing concentrations of F−.; b) 
Fluorescence spectra of 115 (8×10-6 M) in CH3CN upon addition of increasing concentrations of Cu2+. 
 
Figure 3-12 a) Stern-Volmer plot of 114 with F-; b) Job plot of a 1:1 complex of 114 with F-.  
Figure 3-11b showed the gradual reductions in fluorescence intensity for receptor 115 
upon addition of Cu2+. From the fluorescence titration profiles, the association constant for 
115*Cu2+ was found to be 1.43×105, according to the Stern-Volmer plot (Figure 3-13a). 
Based on the fluorescence titration measurement, detection limit of receptor 115 for Cu2+ was 
found to be 2.4×10-6 M. In the Job’s plot (Figure 3-13b), a maximum fluorescence change 
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was observed with a 0.5 molar fraction of receptor to Cu2+ ion for 115, which indicated the 
formation of a 1:1 complex.   
 
Figure 3-13 a) Stern-Volmer plot of 115 with Cu(ClO4)2; b) Job plot of a 1:1 complex of 115 (8 × 10-5 M) with 
Cu2+. 
3.4.2 Determination of selectivity by competition experiments 
Selectivity of receptor 114 for F− ion was further ascertained with competition 
experiments (Figure 3-14a). It was found that the fluorescence intensity of receptor 114 in the 
presence of 10 equivalents of F− ion was unaffected by the addition of 10 equivalents of 
competing anions (Cl-, Br-, I-, NO3-, HSO4-, AcO-). This observation indicates that 114 is 
selective towards the recognition of F− ion over other metal ions. For receptor 115, it can be 
seen from the competition experiment results (Figure 3-14b) that the fluorescence intensity of 
receptor 115 in the presence of 10 equivalents of ion Cu2+ was also unaffected by the addition 
of 10 equivalents of competing metal ions (Li+, Na+, K+, Ca2+, Mg2+, Co2+, Ni2+, Hg2+, Pb2+, 
Cd2+, or Zn2+).  
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Figure 3-14 Competitive experiments of 114 and 115. a) Competitive experiments in the 114 + F- system with 
interfering anions. [114] = 7.2 µM, [F-] = 72 µM, and [Xn-] = 72 µM in DMSO. λex = 375 nm; b) competitive 
experiments in the 115 + Cu2+ system with interfering metal ions. [115] = 80 µM, [Cu2+] = 800 µM, and [X+] = 
800 µM in CH3CN. λex = 518 nm 
3.4.3 Conclusion 
In summary, five BODIPY fluorophores modified at the meso-position were synthesized 
using the Mannich reaction that was developed in our laboratory. Among these, BODIPY 
bearing aza-15-crown-5 114 and aza-18-crown-6 115 modifications showed selective binding 
to F− in DMSO and Cu2+ in acetonitrile, respectively, leading to ion concentration-dependent 
decreases in fluorescence emission intensity. However, the mechanism of the fluorescent 
quenching remains unknown. 
3.5 Isothiocyanate and azide BODIPY 
Syntheses of isothiocyanate and azide BODIPY were attempted in this thesis to expand 
the scope of BODIPY in labeling biomolecules.   
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Scheme 3-8 Regents and conditions: i) NaNO2, HOAc. 0oC, 3h; ii) NaOMe, Et2O, 0oC; iii) HOAc, NaOAc, Zn 
dust, 95-110 oC; iv) , r.t.; v) NaOH, diethylene glycol, 220 oC; vi)   NCS, CH2Cl2.                                                                                                        
2-(Ethoxycarbonyl)-3,4-dimethylpyrrol 121 was prepared from diethyl oximidomalonate 
117 and 2-methyl-3-oxa-l-butene 1-oxide sodium salt 120 by Paal-Knorr pyrrole synthesis in 
the presence of zinc dust (Scheme 3-8).[136] To obtain a more stable dipyrrolemethane 
intermediate, the pyrrole ester 121 was used to prepare the 5-phenyl-dipyrrolemethane instead 
of 3,4-dimethylpyrrole. After removal of the ester side chain on the 1,9-positions, chlorination 
of the 5-phenyl-dipyrrolemethane 123 was attempted by treatment with N-chlorosuccinimide 
(NCS), which, however, failed to give the desired mono-chlorinated product 124. 
As alternatives, 4,4-difluoro-5-chloro-1,3,8-trimethyl-2-ethyl-4-bora-3a,4a-diaza-s-
indacene 127 and 4,4-diphenyl-5-chloro-1,3,8-trimethyl-2-ethyl-4-bora-3a,4a-diaza-s-
indacene 130 were synthesized according to literature procedures (Scheme 3-9).[137] The 
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monochlorinated BODIPY 127 and 130 were then treated with sodium azide at 60oC, which, 
however, also failed to give the desired azido-BODIPY products 128 or 131.   
 
Scheme 3-9 Regents and conditions: i) SOCl2, THF. -78 oC, 3h; ii) acylating agent, THF, 14h; iii) POCl3, Et3N, 
BF3, CH2Cl2; iv) Et3N, BBrPh2 (129), CH2Cl2, r.t. 
We next sought to prepare amino-BODIPY as precursor for the synthesis of azido- and 
isothiocyanato-BODIPY.  
 
Scheme 3-10 Regents and conditions: i) NaNO2 (aq) AcOH/Ac2O (1:1), 100oC, 2h; ii) Et3N, BBrPh2 (129), 
CH2Cl2, rt, 2 h; iii) 2-azido-1,3-dimethylimidazolinium hexafluorophosphate, base, CH2Cl2; iv) iv) CS2, Et3N, 
Boc2O, EtOH. r.t. 
Following a literature procedure,[138] the 4,4-diphenyl analogue 132 was prepared from 
2,4-dimethyl-3-ethylpyrrole 90 in a one-pot fashion (Scheme 3-10). The identity of the 
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product 132 was confirmed by X-ray crystallography. Transformations of 132 into the 
corresponding azido- and isothiocyanato BODIPY 133 and 134, respectively, are ongoing in 
our laboratory. 
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Chapter 4 Synthesis of PNAs via Staudinger reaction 
4.1 Overview of Staudinger ligation applied in peptide synthesis 
The Staudinger ligation reaction between azides and phosphines (Scheme 4-1b), first 
demonstrated by Bertozzi and co-workers in 2000,[139] is a modification of the classical 
Staudinger reaction (Scheme 4-1a) where treatment of azido compound 135 with phosphine 
leads to the reduction of azide to amine 137. 
 
Scheme 4-1. a) Staudinger reaction; b) Staudinger ligation reaction. 
The Staudinger ligation occurs between an azide 138 and a thioester of phosphinothiol 
139 to produce an aza-ylide intermediate 140. The nitrogen atom of the iminophosphorane 
140 is nucleophilic, which can be acylated by a thioester via formation of a tetrahedral 
intermediate 141. In aqueous media, the intermediate rearranges to produce an 
amidophosphonium salt 142, which hydrolyzes to give an amide 143 and o-
(diphenylphosphinyl)-benzenethiol 144. The Staudinger ligation is therefore a useful 
approach for chemical ligation. It is noteworthy that the method is “traceless”, leaving no 
residual atoms from the phosphinothiol remaining in the final product. 
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Scheme 4-2. Proposed mechanism of the Staudinger ligation reaction. 
The Staudinger ligation, as a chemoselective ligation chemistry with fewer additives, has 
been developed for use with biological samples. Nilsson’s group reported[140] its application 
in peptide synthesis, where a peptide with a C-terminal phosphinothioester 145 is coupled to 
another peptide with an N-terminal α-azido group 146 to generate a single peptide 147 
without residual atoms containing (Scheme 4-3). 
 
Scheme 4-3. Staudinger ligation in peptide synthesis.  
4.2 Synthesis of PNAs by Staudinger ligation reaction 
Normally synthesis of PNA oligomers involves coupling the amino group to carboxyl in 
the presence of activators. These coupling reactions often give rise to products in rather poor 
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yields, particularly with bases such as guanine. In this thesis the Staudinger ligation was 
explored for the synthesis of PNA. 
As a model study, uracil PNA monomers were prepared. Alkylation of uracil 148 gave 
the corresponding tert-butyl ester 149, which was subsequently hydrolyzed to give the 
corresponding acid 150 (Scheme 4-4).  
 
Scheme 4-4. Reagents and conditions: i) tert-butyl bromoacetate, DMF, K2CO3; ii) TFA, CH2Cl2 
The protected N-(2-aminoethyl)glycine unit 153 was prepared from ethylenediamine 151 
in two steps (Scheme 4-5).  Coupling of the uracil acetic acid 150 with the backbone 151 gave 
the corresponding fully protected uracil monomer 154. Deprotection of the benzyl ester gave 
the corresponding monomer acid 155.   
 
Scheme 4-5 Reagents and conditions: iii) Di-tert-butyl dicarbonate, CH2Cl2.; iv) benzyl bromoacetate, (i-
Pr)2NEt, 1,4-dioxane; vi) H2, 10% Pd/charcoal, MeOH-EtOAc (6 mL, 5:1, v/v). 
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In order to transform monomer acid 155 into corresponding thioester, 
diphenylmethylphosphinothiol was required. Chloromethylphosphonic dichloride 156 was 
first treated with phenylmagnesium bromide to generate the phosphine oxide 157 via a 
Grignard reaction (Scheme 4-6).[140] A mixture of diphenyl chloromethylphosphonate 157, 
thioacetic acid and triethylamine was then heated at reflux under nitrogen. The resulting 
product was purified by chromatography and then treated with decolorizing charcoal to give 
the thiophosphine oxide 158 in 39% yield. The diphenyl acetylthiomethyl phosphonate 158 
was then reduced into phosphinothioester 159 via treatment with an excess of trichlorosilane 
in chloroform.  Hydrolysis of the phosphinoester was performed in methanol with sodium 
hydroxide under nitrogen, which gave phosphinoester 160 in 30% yield. Coupling of the 
uracil monomer acid 155 with phosphinoester 160 gave the corresponding uracil-PNA 
monomer 161.  
 
Scheme 4-6 Reagents and conditions: i) Phenylmagnesium bromide, THF; ii) thioacetic acid, (i-Pr)2NEt, THF; 
iii) trichlorosilane, N2, CHCl3.; iv) NaOH, N2, MeOH.; v) 155, DCC, DMF. 
 For Staudinger ligation, another uracil building block 165 incorporating an azido group 
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is required. This azido monomer was prepared by coupling uracil acid 150 with benzyl 2-
azidoethylglycine 164, which was readily prepared in two steps from aminoethyl chloride 
hydrochloride 162 (Scheme 4-7).  
 
Scheme 4-7 Reagents and conditions: i) NaN3, H2O, 80oC; ii) benzyl bromoacetate, (i-Pr)2Net, DMF.; iii) 143, 
DCC, DMF.  
With the azido- 165 and phosphinothioester 161 PNA building blocks ready, ligation 
reactions were attempted (Scheme 4-8). These reactions have failed to give the desired PNA 
dimer 166 to date. Work is currently ongoing to further investigate this ligation reaction. 
 
Scheme 4-8 Reagents and conditions: i) THF, H2O, r. t.
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Chapter 5 Experimental 
5.1 Instrumentation 
1H NMR spectra were measured at 300 or 600 MHz with Broker Avance 300 and 600 
Digital NMR spectrometers with a 7.05 and 14.1 Tesla Ultrashield magnet, respectively. l3C 
NMR spectra were measured at 75 MHz or 151 MHz, 31P at 121 MHz, l1B at 96 MHz or 193 
MHz, and l9F at 282 MHz, respectively, with the same instrument. Chemical shifts and 
coupling constants (J values) were given in ppm and Hz, respectively. The following 
deuterated solvents from C/D/N isotopes Inc. were used for preparation of NMR samples: 
dimethyl-d6 sulfoxide with 0.05% tetramethylsilane internal standard (99.9 atom % D), 
deuterated chloroform (99.9 atom % D), and deuterium oxide (99.9 atom % D). Low and high 
resolution mass spectra were obtained with Kratos Concept 1 S high resolution mass 
spectrometer using electron impact or fast atom bombardment sources interfaced with DART 
32 bit acquisition system through a Sun Sparcstation 10 and Mach 3 software. UV/vis spectra 
were obtained using a Thermospectronic/Unicam UVNis spectrometer configured to the 
Vision32 software. Fluorescent spectra were recorded using QuantaMaster model QM-2001-4 
cuvette-based L-format scanning spectrofluorometer from Photon Technology International 
(PTI) interfaced with FeliX32 software.	   
X-­Ray	  crystallography	  (performed	  by	  Dr.	  Alan	  Lough	  at	  the	  University	  of	  Toronto)	  
Data were collected on a Bruker-Nonius Kappa-CCD diffractometer using 
monochromated Mo-Kα radiation and were measured using a combination of φ scans and ω 
scans with κ offsets, to fill the Ewald sphere. The data were processed using the Denzo-SMN 
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package1. Absorption corrections were carried out using SORTAV2. The structure was 
solved and refined using SHELXTL V6.13 for full-matrix least-squares refinement that was 
based on F2. All H atoms were included in calculated positions and allowed to refine in 
riding-motion approximation with Uiso tied to the carrier atom. 	  
5.2 Chromatography 
Silica gel (EMD, >230 mesh) was used for short-column chromatography. Thin layer 
chromatography was performed on Silicycle SiliaPlate F-254 TLC plates using the following 
solvent mixtures: 
System A: hexane–dichloromethane (70:30, v/v) 
System B: hexane–dichloromethane (60:40, v/v) 
System C: hexane–dichloromethane (50:50, v/v) 
System D: hexane–dichloromethane (40:60, v/v) 
System E: DCM 
System F: Methanol–dichloromethane (5:95, v/v) 
System G: methanol–dichloromethane (10:90, v/v) 
5.3 Solvents and Chemicals 
        Benzene and diethyl ether were dried by heating under reflux over sodium in the 
presence of benzophenone for 4 h and then distilled. N,N-Diethylamine, N,N-
diisopropylamine, piperidine, pyridine and CH2Cl2 were dried by heating under reflux over 
calcium hydride for 4 h and then distilled. Methanol and ethanol were dried by heating over 
trace amount of iodine activated magnesium with a magnesium loading of 3.0-4.0 g/L.  All 
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other reagents were purchased from Sigma-Aldrich or VWR Canlab without further 
purification prior to use unless stated otherwise. 
5.4 Preparation of compounds 
Ethyl 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carboxylate 167 [141] 
 
A cold (ice–water bath) solution of sodium nitrite (35.00 g, 0.51 mol) in water (50 mL) 
was added dropwise over 3 h to a stirred cooled (ice-water bath) mixture of ethyl acetoacetate 
(43.00 g, 0.33 mol) and acetic acid (150 mL) in a three-neck flask equipped with a 
thermometer. After the mixture was stirred for another 24 h at room temperature, 
acetylacetone (37.5 g, 0.038 mol) was added, followed by the addition of zinc dust (48.00 g, 
0.74 mol) in portions (3~4 g per portion) at a rate so that the reaction temperature did not 
exceed 80°C. After the addition of zinc was complete, the mixture was heated at 110°C 
overnight. The products were poured into ice-water (500 mL) and cooled at -4°C for 2 h. The 
solid was collected by filtration and further washed with water (3×300 mL). The product was 
then heated under reflux in 100% ethanol (300 mL) and filtered while hot. The filtrate was 
allowed to stand at 4°C overnight to give the title compound as light yellow crystals (44.20 g, 
65%).  
δH[CDCl3, 300.1 MHz]:  1.39 (3 H, t, J = 7.2), 2.47 (3 H, s), 2.54 (3 H, s), 2.61 (3 H, s), 4.35 
(2 H, q, J = 7.2), 9.25 (1 H, br, s) 
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2, 4-Dimethyl-3-ethyl-1H-pyrrole 90 [141] 
 
A mixture of ethyl 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carboxylate (44.00 g, 0.26 mol) 
and KOH (35.00 g, 0.89 mol) were suspended in diethylene glycol (250 mL) in a three-neck 
flask equipped with a thermometer and a condenser. Hydrazine hydrate (14.00 g, 0.28 mol) 
was added. The mixture was stirred under reflux for 2 h while a steam of nitrogen was 
bubbled into the reaction mixture. The distillates at 60-100°C were discarded and the residue 
was heated under reflux for another 1 h. The nitrogen flow was increased and the distillates at 
120-200°C were collected. The latter distillate was diluted with water (50 mL) and extracted 
with ether (2×60 mL). The organic layer was dry (MgSO4) and concentrated under reduced 
pressure, followed by distillation under vacuum to give the titled product (17.21 g, 67%) as a 
light yellow oil. This compound should be well desiccated and stored in a refrigerator in dark. 
δH[CDCl3, 300.1 MHz]: 1.26 (3 H, t, J = 7.4), 2.21 (3 H, s), 2.31 (3 H, s), 2.58 (2 H, q, J = 
7.4), 6.51 (1 H, s), 7.52 (1 H, broad s, NH) 
4,4-Difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 
 
A solution of distilled acetyl chloride 91 (0.21 mL, 2.9 mmol) in dry dichloromethane (10 
mL) was added drop-wise to a stirred degassed solution of 3-ethyl-2,4-dimethylpyrrole 90 
(1.10 mL, 8.15 mmol) in dry dichloromethane (15 mL). After the mixture was heated under 
	   79	  
reflux for 3 h, the solvents were evaporated under reduced pressure. The residue was co-
evaporated with dry toluene (3×20 mL) and then re-dissolved in dry dichloromethane (20.0 
mL), followed by addition of dry triethylamine (1.1 mL, 7.9 mmol). After 15 min boron 
trifluoride diethyl etherate (0.93 mL, 7.4 mmol) was added and the mixture was stirred under 
reflux for 3 h. Upon cooling to room temperature, the products were extracted successively 
with water (30 mL) and brine (3×30 mL). The organic layer was separated, dried (MgSO4) 
and evaporated under reduced pressure. The residue was purified by column chromatography 
on silica gel. The appropriate fractions, which were eluted with dichloromethane–hexane 
(50:50 v/v), were combined and evaporated under reduced pressure to give the title compound 
as an orange solid (0.50 g, 54%).  
HR-Fab found [M+H]+ =318.19648, 12C181H2511B19F214N2 requires 318.20788 
Rf (System D): 0.57  
δH[CDCl3, 300.1 MHz]: 1.06 (6 H, t, J = 7.5), 2.34 (6 H, s), 2.42 (4 H, q, J = 7.5), 2.52 (6 H, 
s), 2.61 (3 H, s). 
δC[CDCl3, 75.5 MHz]: 12.4, 14.4, 14.9, 16.9, 17.1, 131.6, 132.3, 136.3, 139.7, 151.8 
δB[CDCl3, 192.6 MHz]:  0.66 (t, J = 33) 
δF[CDCl3, 282.4 MHz]:  -146.0 (q, J = 33) 
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1,3,4,4,5,7,8-Heptamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 93[126] 
 
A solution of methylmagnesium bromide in diethyl ether (1.02 mL, 3 M, 3.06 mmol) was 
added to a solution of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene 92 (0.107 g 0.336 mmol) in dry dichloromethane (30 mL) at 0°C. After the mixture 
was stirred for 5 min (TLC: dichloromethane–hexane, 40:60 v/v), water (2 mL) was added, 
and the resulting mixture was washed successively with water (30 mL) and brine (30 mL). 
The layers were separated and the organic layer was dried (MgSO4) and concentrated under 
reduced pressure. The residue was purified by column chromatography on silica gel. The 
appropriate fractions, which were eluted with dichloromethane–hexane (20:80 v/v) were 
combined and evaporated under reduced pressure to give the title compound as an orange 
solid (0.071 g, 67%). 
HR-Fab found [M+H]+ =310.25311, 12C201H3111B14N2 requires 310.25803  
Rf (System A): 0.80 
δH[CDCl3, 300.1 MHz]: 0.26 (6 H, s), 1.09 (6 H, t, J = 7.5), 2.39 (6 H, s), 2.46 (4 H, q, J = 
7.5), 2.48 (6 H, s), 2.69 (3 H, s)  
δC[CDCl3, 75.5 MHz]: 14.3, 14.8, 15.0, 17.5, 17.6, 53.43, 130.3, 131.9, 132.2, 139.8, 148.7 
δB[CDCl3, 96.3 MHz]: -1.55 
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4,4-Dimethoxy-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 94  
 
(Method A: prepared from 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene 86)[127]  
A solution of sodium methoxide in methanol (0.40 mL, 1.29 mmol, taken from a stock 
solution prepared by the addition of 0.74 g sodium metal to 10 mL methanol) was added to a 
solution of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 
(0.104 g 0.327 mmol) in dry dichloromethane (30 mL) at 0°C. The mixture was stirred under 
reflux for 23 h (TLC: dichloromethane–methanol, 92:8 v/v). The resulting mixture was 
washed successively with distilled water (40 mL) and aqueous saturated sodium bicarbonate 
solution (30 mL). The layers were separated and the organic layer was dried (MgSO4) and 
concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel. The appropriate fractions, which were eluted with dichloromethane–methanol (98:2 
v/v) were combined and evaporated under reduced pressure to give the title compound as an 
orange solid (0.071 g, 63%). 
(Method B: prepared from 4,4-bis(trichloroacetoxy)-1,3,5,7,8-pentamethyl-2,6-diethyl-4-
bora-3a,4a-diaza-s-indacene 96) 
Dry methanol (0.10 mL) and 1,8-diazabicycloundec-7-ene (DBU, 0.10 mL, 0.67 mmol) 
were successively added to a solution of 4,4-bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-
pentamethyl-4-bora-3a,4a-diaza-s-indacene 96 (150 mg, 0.280 mmol) in dry dichloromethane 
(10 mL). The mixture was stirred for 5 h and the resulting solution was washed successively 
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with saturated aqueous sodium bicarbonate solution (10 mL) and brine (10 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v) were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (87 mg, 91%).  
FAB-MS [M+H]+ found 342, C20H31BN2O2 requires 342. 
Rf (System D): 0.38 
δH[CDCl3, 300.1 MHz]: 1.07 (6 H, t, J = 7.5), 2.37 (6 H, s), 2.43 (4 H, q, J = 7.5), 2.50 (6 H, 
s), 2.63 (3 H, s), 2.82 (6 H, s)  
δC[CDCl3, 75.5 MHz]: 12.1, 14.6, 15.1, 17.1, 17.2, 49.0, 131.9, 133.1, 134.2, 139.1, 152.0 
δB[CDCl3, 96.3 MHz]: 2.43 
 
4,4-Diphenyl-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 95 [128]  
 
 A solution of phenylmagnesium bromide in diethyl ether (1.02 mL, 3 M, 3.06 mol) was 
added at 0°C to a solution of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene 92 (0.110 g, 0.346 mmol) in dry dichloromethane (30 mL). After the 
mixture was stirred at 0°C for 10 min (TLC: dichloromethane–hexane, 40:60 v/v), water (2 
mL) was added, and the resulting mixture was washed successively with distilled water (30 
mL) and brine (30 mL). The organic layer was dried (MgSO4) and concentrated under 
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reduced pressure. After the products were evaporated under reduced pressure, the residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were 
eluted with diethyl ether–hexane (15:85 v/v) were combined and evaporated under reduced 
pressure to give the title compound as an orange solid (0.098 g, 65%). 
HR-Fab found [M+H]+ = 434.26879, 12C301H3511B14N2 requires 434.28933 
Rf (System A): 0.63 
δH[CDCl3, 300.1 MHz]: 1.05 (6 H, t, J = 7.5), 1.80 (6 H, s), 2.42 (4 H, q, J = 7.5), 2.44 (6 H, 
s), 2.74 (3 H, s), 7.28 (10 H, m)  
δC[CDCl3, 75.5 MHz]: 14.7, 14.8, 15.1, 17.5, 18.0, 125.5, 127.2, 128.1, 132.3, 132.4, 133.5, 
133.7, 140.1, 151.2 
δB[CDCl3, 96.3 MHz]: -0.36 
 
4,4-Bis(trichloroacetoxy)-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene 96 
 
Dichloroacetic acid (143 µl, 1.73 mmol) was added to a solution of 4,4-dimethoxy-
1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 (60 mg, 0.175 mmol) in 
dry dichloromethane (1.5 mL). After 18 h, complete consumption of the starting material was 
observed by TLC (hexane-dichloromethane, 20:80 v/v). The resulting mixture was diluted 
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with dichloromethane (10 mL) and washed successively with water (15 mL) and saturated 
aqueous sodium bicarbonate solution (15 mL). The layers were separated and the organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
hexane–dichloromethane (60:40 v/v) were combined and evaporated to give the title 
compound as an orange solid (90 mg, 95%). 
EI found M+ = 536, C22H27BCl4N2O4 requires  536. 
Rf (System F): 0.42 
δH[CDCl3, 300.1 MHz]: 1.03 (6 H, t, J = 7.6), 2.37 (4 H, q, J = 7.6), 2.37 (6 H, s), 2.44 (6 H, 
s), 2.70 (3 H, s), 5.88 (2 H, s) 
δC[CDCl3, 75.5 MHz]: 12.6, 14.7, 17.2, 66.2, 132.8, 133.1, 137.8, 140.8, 150.4, 163.2 
δB[CDCl3, 96.3 MHz]: 0.54 
 
2,6-Diethyl-4,4-diethoxy-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 97 
 
Dry ethanol (0.10 mL) and DBU (0.080 mL, 0.54 mL) were successively added to a 
solution of 4,4-bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-
indacene 96 (100 mg, 0.187 mmol) in dry dichloromethane (10 mL). The mixture was stirred 
for 3 h and the resulting solution was washed successively with saturated aqueous sodium 
bicarbonate solution (10 mL) and brine (10 mL). The organic layer was dried (MgSO4) and 
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concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel. The appropriate fractions, which were eluted with dichloromethane–methanol (99:1 
v/v) were combined and evaporated under reduced pressure to give the title compound as an 
orange solid (52 mg, 75%).  
ESI-MS found [M+Na]+ = 393.2. C22H35BN2NaO2+ requires 393.27.  
Rf: 0.47 (System F). 
δH[CDCl3]: 0.99 (6 H, t, J = 7.0), 1.05 (6 H, t, J = 7.5), 2.35 (6 H, s), 2.42 (4 H, q, J = 7.5), 
2.54 (6 H, s), 2.62 (3 H, s), 2.91 (4 H, q, J = 7.0). 
δC[CDCl3]: 12.4, 14.5, 15.1, 17.0, 17.2, 17.7, 56.3, 131.8, 133.0, 134.0, 138.9, 152.2. 
δB[CDCl3]: -1.76 
  
2,6-Diethyl-4,4-diphenoxy-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 98 
 
Phenol (65 mg, 0.69 mmol) and DBU (0.080 mL, 0.54 mmol) were successively added to 
a solution of 4,4-bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-
s-indacene 96 (100 mg, 0.187 mmol) in dry dichloromethane (10 mL). The mixture was 
stirred for 30 min and the resulting solution was washed successively with saturated aqueous 
potassium carbonate solution (3×10 mL) and brine (10 mL). The organic layer was dried 
(MgSO4) and concentrated under reduced pressure. The residue was purified by column 
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chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–hexane (50:50 v/v) were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (60 mg, 69%). 
ESI-MS found [M+Na]+ = 489.2. C30H35BN2NaO2+ requires 489.27.  
Rf: 0.32 (System C). 
δH[CDCl3]: 0.93 (3 H, t, J = 7.5), 0.96 (4 H, q, J = 7.5), 2.37 (6 H, s), 2.50 (6 H, s), 2.69 (3 H, 
s), 6.51 (4 H), 6.73 (2 H), 7.02 (4 H). 
δC[CDCl3]: 12.7, 14.6, 14.8, 17.0, 17.1, 118.6, 119.1, 128.9, 132.7, 132.9, 136.1, 139.2, 
152.7, 156.8. 
δB[CDCl3]: 0.67 
 
2-[(Z)-(3,5-Dimethyl-4-ethyl-2H-pyrrol-2-ylidene)ethyl]-1-(1,3,2-dioxaborolan-2-yl)-3,5-
dimethyl-4-ethyl-1H-pyrrole 99 
 
To a solution of 4,4-bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-
3a,4a-diaza-s-indacene 96 (180 mg, 0.336 mmol) in dry dichloromethane (10 mL) was added 
a solution of ethylene glycol (16 µl, 0.29 mmol) and DBU (0.15 mL, 1.00 mmol) in 
dichloromethane (3.0 mL). The mixture was stirred for 30 min and the resulting solution was 
washed successively with saturated aqueous sodium bicarbonate solution (10 mL) and brine 
(10 mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. The 
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residue was purified by column chromatography on silica gel. The appropriate fractions, 
which were eluted with dichloromethane–methanol (99:1 v/v) were combined and evaporated 
under reduced pressure to give the title compound as an orange solid (29 mg, 29% based on 
ethylene glycol).  
ESI-MS found [M+H]+ = 341.1. C20H30BN2O2+ requires 341.24.  
Rf: 0.43 (System F). 
δH[CDCl3]: 1.02 (6 H, t, J = 7.5), 2.31 (6 H, s), 2.39 (4 H, q, J = 7.5), 2.48 (6 H, s), 2.60 (3 H, 
s), 4.18 (4 H, s). 
δC[CDCl3]: 12.5, 14.5, 15.0, 17.2, 17.5, 65.2, 132.1, 133.1, 136.1, 139.8, 151.4 
δB[CDCl3]: 5.89 
 
1-(1,3,2-Benzodioxaborol-2-yl)-2-[(Z)-(3,5-dimethyl-4-ethyl-2H-pyrrol-2-ylidene)ethyl]-
3,5-dimethyl-4-ethyl-1H-pyrrole 100 
  
A solution of catechol (20 mg, 0.18 mmol) and DBU (0.080 mL, 0.54 mmol) in 
tetrahydrofuran (THF, 3.0 mL) was added slowly to a solution of 4,4-bis(dichloroacetoxy)-
2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 96 (100 mg, 0.187 mmol) in 
dry THF (5.0 mL). The mixture was stirred for 30 min and the products were concentrated 
under reduced pressure. The resulting mixture was diluted with dichloromethane (10 mL) and 
washed successively with saturated aqueous sodium bicarbonate solution (8 mL) and brine (8 
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mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel. The appropriate fractions, 
which were eluted with hexane–dichloromethane (90:10 v/v) were combined and evaporated 
under reduced pressure to give the title compound as an orange solid (32 mg, 44%.).  
ESI-MS found [M+H]+ = 389.1. C24H30BN2O2+ requires 389.24.  
Rf: 0.42 (System C). 
δH[CDCl3]: 1.00 (6 H, t, J = 7.5), 2.04, (6 H, s), 2.36 (10 H, br, m), 2.66 (3 H, s), 6.77 (4H, s). 
δC[CDCl3]: 12.6, 14.6, 14.9, 17.1, 17.2, 108.7, 119.3, 128.8,  132.5, 133.0, 137.0, 139.6, 
152.0, 153.5 
δB[CDCl3]: 6.99 
 
Uridine-BODIPY conjugate 101 
 
A solution of uridine (45.0 mg, 0.184 mmol) and 1,8-diazabicycloundec-7-ene (0.080 
mL, 0.54 mmol) in DMF (3.0 mL) was added slowly to a solution of 4,4-
bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 96 
(100 mg, 0.187 mmol) in dry DMF (5.0 mL). After the mixture was stirred for 30 min, the 
solvent was removed under reduced pressure. The resulting mixture was diluted with 
dichloromethane (10 mL) and washed successively with saturated aqueous sodium 
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bicarbonate solution (8 mL) and brine (8 mL). The organic layer was dried (MgSO4) and 
concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel. The appropriate fractions, which were eluted with dichloromethane–methanol (99:1 
v/v) were combined and evaporated under reduced pressure to give the uridine-BODIPY 
conjugate 101 as an orange solid (43 mg, 44%).  
ESI-MS found [M+H]+ = 523.2. C22H36BN2NaO2+ requires 523.27.  
Rf: 0.27 (System F). 
δH[DMSO-d6]: 0.97 (3 H, t, J = 7.4), 0.99 (3 H, t, J = 7.3), 2.27 (3 H, s), 2.30 (3 H, s), 2.34, 
2.37, 2.40 (integrate 7 H), 2.55 (3 H, s), 2.58 (3 H, s), 3.57 (m, 2 H, H-5’, H-5’’), 4.08 (1 H, 
dd, J = 3.5 and 7.5, H-4’), 4.61–4.68 (2 H, m, H-2’ and H-3’), 5.02 (1 H, ex, 5’-OH), 5.61 (1 
H, d, J = 8.0), 5.92 (1 H, d, J = 2.2, H-1’), 7.84 (1 H, d, J = 8.0), 11.3 (1 H, s, ex). 
δH[DMSO-d6]: 6.90 
 
4,4-Bis(dichloroacetoxy)-2,6-diethyl-8-(2-(N,N-diethylamino)ethyl)-1,3,5,7-tetramethyl-
4-bora-3a,4a-diaza-s-indacene 102 
 
Diethylamine (1.0 mL, 9.7 mmol, used directly from package) was added to a solution of 
4,4-bis(dichloroacetoxy)-2,6-diethyl-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 96 
(100 mg, 0.187 mmol) in dry dichloromethane (5 mL). After the mixture was stirred for 2 d, 
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the products were diluted with dichloromethane (5 mL) and washed successively with 
saturated aqueous sodium bicarbonate solution (8 mL) and brine (8 mL). The organic layer 
was dried (MgSO4) and concentrated under reduced pressure. The residue was purified by 
column chromatography on silica gel. The appropriate fractions, which were eluted with 
hexane–dichloromethane (90:10, v/v) were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (48 mg, 41%).  
ESI-MS found [M+H]+ = 622.1, C27H39BCl4N3O4+ requires 622.17. 
Rf: 0.36 (System F).  
δH[CDCl3]: 1.03 (6 H, t, J = 7.6), 1.07 (6 H, t, J = 7.0), 2.37 (4 H, q, J = 7.6), 2.44 (12 H, s), 
2.66 (4 H, q, J = 7.0), 2.75 (2 H, m), 3.33 (2 H, m), 5.87 (2 H, s). 
δC[CDCl3]: 11.5, 12.6, 13.8, 14.6, 17.3, 28.3, 46.5, 54.9, 66.2, 132.7, 133.1, 137.2, 143.4, 
150.9, 163.2. 
δB[CDCl3]: 0.49 
 
2,6-Diethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(N,N-diethylaminoethyl)-4-bora-3a,4a-
diaza-s-indacene 104 
 
(Method A: preparation by treating 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-
bora-3a,4a-diaza-s-indacene 92 with diethylamine) 
N B N
N
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Diethylamine (0.65 mL, 6.30 mmol) was added to a solution of 4,4-difluoro-1,3,5,7,8-
pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 (100 mg, 0.31 mmol) in dry 
dichloromethane (4 mL) in a Reacti vial. After the mixture was heated at 40˚C for 3 d, the 
resulting solution was diluted with dichloromethane (10 mL) and washed successively with 
saturated aqueous ammonium chloride solution (2×10 mL) and brine (10 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v) were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (78 mg, 62%).  
(Method B: preparation by treating 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-
bora-3a,4a-diaza-s-indacene 92 with tetraethylmethane diamine)  
Tetraethylmethane diamine (0.89 mL, 4.5 mmol) was added to a solution of 4,4-difluoro-
1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (75 mg, 0.24 mmol) in dry 
tetrahydrofuran (4 mL) in a Reacti vial. After the mixture was heated at 40˚C overnight, the 
resulting solution was diluted with dichloromethane (10 mL) and washed successively with 
saturated aqueous ammonium chloride solution (2×10 mL) and brine (10 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v) were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (78 mg, 93%).  
Rf: 0.4 (System F). 
HR-MS (EI) found: 403.29742, 12C231H3611B19F214N3 required: 403.29703  
δH[CDCl3]: 1.06 (12 H, t, J = 7.3), 2.38–2.47 (10 H, m), 2.51 (6 H, s), 2.65 (6 H, m), 3.25 (2 
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H, m). 
δC[CDCl3]: (75.5 MHz): δ = 11.6, 12.4, 13.5, 14.8, 17.2, 27.8, 46.6, 55.1, 131.2, 132.6, 135.9, 
142.3, 152.3. 
δB[CDCl3]: δ = 0.60 (t, J = 33.2) 
 
2,6-Diethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(N,N-dimethylaminoethyl)-4-bora-3a,4a-
diaza-s-indacene 105 
 
Dimethylamine (1 mL, 2 M in THF) was added to a solution of 4,4-difluoro-1,3,5,7,8-
pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 (100 mg, 0.31 mmol) in dry 
dichloromethane (4 mL) in a Reacti vial. After the mixture was heated at 40˚C for 4 d, the 
resulting solution was diluted with dichloromethane (10 mL) and washed successively with 
saturated aqueous ammonium chloride solution (2×10 mL) and brine (10 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v) were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (72 mg, 61%).  
HR-MS (EI) found 375.26626, 12C211H3211B19F214N3 required 375.26573.  
Rf: 0.44 (System F) 
δH[CDCl3]: 1.07 (6 H, t, J = 7.5), 2.36 (6 H, s), 2.42 (4 H, q, J = 7.5), 2.51 (6 H, s), 2.55 (2 H, 
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m), 3.24 (2 H, m).  
δC[CDCl3]: 12.4, 13.5, 14.8, 17.2, 27.3, 45.5, 60.6, 131.2, 132.7, 135.8, 141.6, 152.4.  
δB[CDCl3]: 0.59 (t, J = 33.2) 
 
2,6-Diethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-(N,N-diisopropylaminoethyl)-4-bora-
3a,4a-diaza-s-indacene 106 
 
(Method A: reaction was carried out in dichloromethane) 
Diisipropylamine (6.73 mL, 47.78 mmol) was added to a solution of 4,4-difluoro-
1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 (300 mg, 0.94 mmol) in 
dry dichloromethane (7 mL) in a Reacti vial. After the mixture was heated at 40˚C for 7 d, the 
resulting solution was diluted with dichloromethane (20 mL) and washed successively with 
saturated aqueous ammonium chloride solution (2×20 mL) and brine (20 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v) were combined and evaporated under reduced pressure 
to recover the starting material (236 mg) and give the title compound as an orange solid (30 
mg, 34%).  
N B N
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(Method B: reaction was carried out in dibromomethane) 
Diisipropylamine (0.89 mL, 6.30 mmol) was added to a solution of 4,4-difluoro-
1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 (100 mg, 0.31 mmol) in 
dry dibromomethane (4 mL) in a Reacti vial. After the mixture was heated at 60˚C for 24 h, 
the resulting solution was diluted with dichloromethane (10 mL) and washed successively 
with saturated aqueous ammonium chloride solution (2×10 mL) and brine (10 mL). The 
organic layer was dried (MgSO4) and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were 
eluted with dichloromethane–methanol (99:1 v/v) were combined and evaporated under 
reduced pressure to give the title compound as an orange solid (102 mg, 75%). 
Rf: 0.46. HR-MS (FAB+) found 432.32985, [M+H]+ required 432.33616.  
δH[CDCl3]: 1.02–1.10 (18 H, m), 2.30–2.47 (10 H, m), 2.52 (6 H, s), 2.73 (2 H, m), 3.14 (2 H, 
sep, J = 6.5), 3.21 (2 H, m).  
δC[CDCl3]: 12.4, 13.4, 14.8, 17.2, 20.9, 29.1, 46.9 (2 signals), 131.3, 132.5, 136.0, 143.2, 
152.0.  
δB[CDCl3]: 0.62 (t, J = 33.2).  
 
	   95	  
2,6-Diethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-((2-piperidin-1-yl)ethyl)-4-bora-3a,4a-
diaza-s-indacene 107 
 
Piperidine (0.63 mL, 6.39 mmol, 20 mol. equiv.) was added to a solution of 4,4-difluoro-
1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 86 (100 mg, 0.31 mmol) in 
dry dichloromethane (4 mL) in a Reacti vial. After the mixture was heated at 40˚C for 4 d, the 
resulting solution was diluted with dichloromethane (10 mL) and washed successively with 
saturated aqueous ammonium chloride solution (2×10 mL) and brine (10 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v) were combined and evaporated under pressure to give 
the title compound as an orange solid (74 mg, 57%).  
HR-MS (EI) found 415.29638, C24H36BF2N3 required 415.29703. 
Rf: 0.42. (System F) 
δH[CDCl3]: 1.07 (6 H, t, J = 7.5), 1.47 (2 H, m), 1.63 (4 H, m), 2.40 (6 H, s), 2.41 (4 H, q, J = 
7.5), 2.51 (10 H, br), 2.59 (2 H, m), 3.26 (2 H, m).  
δC[CDCl3]: 12.4, 13.6, 14.8, 17.2, 24.3, 26.0, 26.6, 54.6, 60.5, 131.2, 132.6, 135.8, 142.4, 
152.2. 
δB[CDCl3]: 0.60 (t, J = 33.6) 
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2,6-Diethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-((2-pyrrolidin-1-yl)ethyl)-4-bora-3a,4a-
diaza-s-indacene 108 
 
Pyrrolidine (0.52 mL, 5.27 mmol) was added to a solution of 4,4-difluoro-1,3,5,7,8-
pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 (100 mg, 0.31 mmol) in dry 
dichloromethane (4 mL) in a Reacti vial. After the mixture was heated at 40˚C for 24 h, the 
resulting solution was diluted with dichloromethane (10 mL) and washed successively with 
saturated aqueous ammonium chloride solution (2×10 mL) and brine (10 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v) were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (80 mg, 63%).  
HR-MS (EI) found 401.28081, 12C231H3411B19F214N3 required 401.28138. 
Rf: 0.36. (System F) 
δH[CDCl3]: 1.06 (6 H, t, J = 7.5), 1.84 (4 H, m), 2.41 (4 H, q, J = 7.5), 2.51 (6 H, s), 2.64 (4 
H, m), 2.73 (2H, m), 3.33 (2 H, m).  
δC[CDCl3]: 12.4, 13.6, 14.8, 17.2, 23.5, 28.0, 57.4, 131.2, 132.6, 135.8, 141.8, 152.3.  
δB[CDCl3]: 0.60 (t, J = 33.2) 
 
N B N
N
F F
	   97	  
2,6-Diethyl-4,4-difluoro-1,3,5,7-tetramethyl-8-((2-morpholin-1-yl)ethyl)-4-bora-3a,4a-
diaza-s-indacene 109 
 
Morpholine (0.52 mL, 6.02 mmol) was added to a solution of 4,4-difluoro-1,3,5,7,8-
pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 (100 mg, 0.31 mmol) in dry 
dibromomethane (4 mL) in a Reacti vial. After the mixture was heated at 60˚C for 7 d, the 
resulting solution was diluted with dichloromethane (10 mL) and washed successively with 
saturated aqueous ammonium chloride solution (2×10 mL) and brine (10 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v) were combined and evaporated under reduced pressure 
to recover the starting material (50 mg) and give the title compound as an orange solid (48 
mg, 66% based on consumed starting material).  
HR-MS (FAB+) found 417.27094, 12C231H3411B19F214N3 required 417.27630. 
Rf: 0.44 (System F) 
δH[CDCl3]: 1.07 (6 H, t, J = 7.6), 2.30–2.46 (10 H, m), 2.51 (6 H, s), 2.54–2.65 (6 H, m), 2.32 
(2 H, m), 3.76 (4 H, t, J = 4.4).  
δC[CDCl3]: 12.4, 13.6, 14.8, 17.2, 26.3, 53.6, 59.9, 67.0, 131.1, 132.7, 135.7, 141.6, 152.5. 
δB[CDCl3]: 0.59 (t, J = 33.2). 
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8-[N,N-Bis(hydroxyethyl)]ethyl-4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene 111 
 
Diethanolamine (330 mg, 3.14 mmol) and N,N-diisopropylethylamine (0.55 mL, 3.16 
mmol) were added to a solution of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene 92 (50 mg, 0.16 mmol) in dioxane–dibromomethane (4 mL, 1:3 v/v)  
and heated at 60˚C for 7 d in a sealed Reacti vial. Upon cooling, the products were diluted 
with dichloromethane (10 mL) and washed successively with saturated aqueous ammonium 
chloride solution (2×10 mL) and brine (10 mL). The layers were separated and the organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v), were combined and evaporated under reduced pressure 
to recover unreacted starting material (40 mg) and give the title compound as an orange solid 
(12 mg, 88% based on consumed starting material).  
MS-ESI+ found 436.3 for [M+H]+, C23H37BF2N3O2+ required: 436.3.   
Rf: 0.45 (System F), 0.74 (System G).  
δH(CDCl3): 1.06 (6 H, t, J = 7.5), 2.38 – 2.46 (10 H, s + q, J = 7.5), 2.51 (6 H, s), 2.78 (4 H, t, 
J = 5.2), 2.82–2.87 (2 H, m), 3.26–3.31 (2 H, m), 3.68 (4 H, t, J = 5.2)  
δC(CDCl3): 12.4, 13.6, 14.8, 17.2, 27.5, 55.8, 56.8, 59.7, 131.1, 132.9, 135.5, 141.2, 152.7.  
δB(CDCl3): 0.54 (t, J = 33). 
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8-{N,N-Bis[(pyridine-2-yl)methyl)]}ethyl-4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-
4-bora-3a,4a-diaza-s-indacene 112 
 
2-Pyridinyl-N-(2-pyridinylmethyl)methanamine (312 mg, 1.57 mmmol) and N,N-
diisopropylethylamine (0.27 mL, 1.55 mmol) were added to a solution of 4,4-difluoro-
1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 (50 mg, 0.16 mmol) in 
dibromomethane (4 mL) and the mixture was heated at 60˚C for 7 d in  a sealed React vial. 
Upon cooling, the products were diluted with dichloromethane (10 mL) and washed 
successively with saturated aqueous ammonium chloride solution (2×10 mL) and water (10 
mL). The layers were separated and the organic layer was dried (MgSO4) and concentrated 
under reduced pressure. The residue was purified by column chromatography on silica gel. 
The appropriate fractions, which were eluted with dichloromethane–methanol (99:1 v/v), 
were combined and evaporated under reduced pressure to recover unreacted starting material 
(36 mg) and give the title compound as an orange solid (20 mg, 86% based on reacted starting 
material).  
MS-ESI+ found 530.3 [M+H]+, C31H39BF2N5+ required: 530.3.  
Rf: 0.24 (System F), 0.60 (System G).  
N
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δH(CDCl3): 1.00 (6 H, t, J = 7.3), 2.23 (6 H, s), 2.35 (4 H, q, J = 7.3), 2.49 (6 H, s), 2.91 (2 H, 
m, br), 3.26 (2 H, m, br), 3.92 (4 H, s), 7.17 (2 H, t, J = 5.5), 7.51 (2 H, d, J = 7.5), 7.67 (2 H, 
t, J = 7.5), 8.53 (2 H, d, J = 4.8).  
δC(CDCl3): 12.4, 13.4, 14.8, 17.1, 27.3, 56.2, 60.8, 122.2, 123.2, 131.3, 132.6, 135.8, 136.4, 
141.8, 149.1, 152.2, 159.3.  
δB(CDCl3): 0.56 (t, J = 33.0). 
 
8-[1-(Aza-12-crown-4)]ethyl-4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene 113 
 
1-Aza-12-crown-4 (110 mg, 0.62 mmol) was added to a solution of 4,4-difluoro-
1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 92 (100 mg, 0.31 mmol) in 
dry dibromomethane (4 mL) in a Reacti vial. After the mixture was heated at 60˚C for 48 h, 
the resulting solution was diluted with dichloromethane (10 mL) and washed successively 
with saturated aqueous ammonium chloride solution (2×10 mL) and water (3×10 mL). The 
organic layer was dried (MgSO4) and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were 
eluted with dichloromethane–methanol (98:2 v/v) were combined and evaporated under 
reduced pressure to recover the starting material (60 mg) and give the title compound as an 
orange solid (38 mg, 60%).  
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HRMS (FAB+) found 506.33206 [M+H]+, C27H43BF2N3O3+ required 506.33655.  
Rf: 0.38 (System F), 0.71 (System G).  
δH(CDCl3): 1.06 (6 H, t, J = 7.6), 2.41 (10 H, s and q, J = 7.5), 2.51 (6 H, s), 2.77–2.85 (6 H, 
m), 3.26 (2 H, m), 3.71 (12 H, s).  
δC(CDCl3): 12.4, 13.7, 14.8, 17.2, 27.5, 54.9, 58.3, 70.2, 70.4, 71.6, 131.2, 132.7, 135.7, 
142.0, 152.3.  
δB(CDCl3): 0.58 (t, J = 33.1). 
 
8-[1-(Aza-15-crown-5)]ethyl-4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene 114 
 
1-Aza-15-crown-5 (344 mg, 1.57 mmol) and N,N-diisopropylethylamine (0.27 mL, 1.55 
mmol) were added to a solution of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene 92 (50 mg, 0.16 mmol) in dibromomethane (4 mL) and the mixture 
was heated at 60˚C for 48 h in a sealed Reacti vial. Upon cooling, the products were diluted 
with dichloromethane (10 mL) and washed successively with saturated aqueous ammonium 
chloride solution (2×10 mL) and water (3×10 mL). The layers were separated and the organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
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by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v), were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (52 mg, 59%).  
HRMS-FAB+ found 550.35764, C29H47BF2N3O4+ required: 550.36277.  
Rf: 0.38 (System F), 0.71 (System G).  
δH(CDCl3): 1.06 (6 H, t, J = 7.5), 2.39 (6 H, s), 2.41 (4 H, q, J = 7.5), 2.50 (6 H, s), 2.79 (2 H, 
m), 2.87 (4 H, t, J = 6.0), 3.24 (2 H, m), 3.67-3.70 (16 H, m).  
δC(CDCl3): 12.4, 13.6, 14.8, 17.2, 27.8, 54.4, 58.1, 69.9, 70.2, 70.4, 71.1, 131.2, 132.6, 135.8, 
141.9, 152.3.  
δB(CDCl3): 0.55 (t, J = 32.2) 
 
8-[1-(Aza-18-crown-6)]ethyl-4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene 115 
 
1-Aza-18-crown-6 (370 mg, 1.40 mmol) and N,N-diisopropylethylamine (0.27 mL, 1.55 
mmol) were added to a solution of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene 92 (50 mg, 0.16 mmol) in dibromomethane (4 mL) and the mixture 
was heated at  60˚C for 48 h in a sealed Reacti vial. Upon cooling, the products were diluted 
N B N
F F
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with dichloromethane (10 mL) and washed successively with saturated aqueous ammonium 
chloride solution (2×10 mL) and water (3×10 mL). The layers were separated and the organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v), were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (65 mg, 68%).  
HRMS (FAB+) found 594.38334 [M+H]+, C31H51BF2N3O5+ required: 594.38898.  
Rf: 0.31 (System F), 0.71 (System G). 
δH(CDCl3): 1.06 (6 H, t, J = 7.5), 2.37 – 2.45 (10 H, s + q, J = 7.5), 2.50 (6 H, s), 2.77–2.82 (2 
H, m), 2.87 (4 H, t, J = 5.6), 3.22–3.28 (2 H, m), 3.64–3.68 (20 H, m).  
δC(CDCl3): 12.4, 13.6, 14.8, 17.2, 27.8, 53.9, 57.4, 69.9, 70.4, 70.7, 70.8, 70.9,  131.2, 132.6, 
135.8, 142.2, 152.2.  
δB(CDCl3): 0.55 (t, J = 33.0). 
 
Diethyl oximidomalonate 117 [142] 
 
A solution of sodium nitrite (51.00 g, 0.72 mol) in water (50 mL) was added dropwise 
over a period of 4 h to a mixture of diethyl malonate (40.00 g, 0.25 mol) and glacial acetic 
acid (120 mL) at 0oC. The reaction mixture was then allowed to warm up to room temperature 
and stirred for 24 h. The products were diluted with diethyl ether (2×100 mL) and the organic 
layer was washed first with water (150 mL), then with saturated aqueous sodium bicarbonate 
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until the washings were alkaline, and finally washed again with water (150 mL). The organic 
layer was dried (MgSO4) and evaporated under reduced pressure to give the title compound as 
a colorless oil (44.10 g, 90%). 
δH(CDCl3): 1.35 (6 H, dt, J = 7.2 and 13.8), 4.39 (4 H, dq, J = 7.8 and 13,8), 10.22 (1H, br, s, 
OH). 
 
2-Methyl-3-oxa-l-butene 1-oxide sodium salt 120[136] 
 
Sodium metal (7.30 g, 0.32 mol) was added with precaution to methanol (50 mL) at 0 oC. 
After the sodium dissolved, the mixture was heated under reflux for 0.5 h. The resulting 
sodium methoxide/methanol solution was then diluted with diethyl ether (350 mL) and cooled 
(ice–water bath). To this mixture was then added over a period of 1 h a mixture of 2-butanone 
(22.80 g, 0.32 mol) and ethyl formate (23.40 g, 0.32 mol) while the reaction temperature was 
kept at 4–6°C. After the addition was complete, stirring was allowed to continue, first at 4–
6°C for 30 min, and then overnight at room temperature. The resulting colorless powder was 
filtered to give the titled salt (23.50 g, 61%). 
δH(CDCl3): 1.62 (s, 3H), 2.13 (s, 3H), 8.99 (s, 1H).  
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2-(Ethoxycarbonyl)-3,4-dimethylpyrrole 121 [136] 
 
Glacial acetic acid (150 mL) was placed in a 1-L round-bottom flask and heated to 85 oC, 
followed by sequential addition of sodium acetate (30.50 g, 0.36 mol), 2-methyl-3-oxa-l-
butene 1-oxide sodium salt 120 (35.4 g, 0.29 mol), diethyl oximidomalonate 117 (52.8 g, 0.28 
mol), and then a solution of acetic acid (70 mL) in water (30 mL). After addition was 
completed, the reaction mixture was heated to 95oC followed by addition of zinc dust (45.00 
g, 0.69 mol) over 45 min while maintaining the reaction temperature at 95–110oC. After the 
addition was complete, the reaction mixture was stirred at the same temperature for additional 
45 min. The hot products were directly poured into ice-water mixture (700 mL). The solid 
was collected by filtration and washed with water. The product was then heated in 100% 
ethanol (400 mL) under reflux and filtered while hot to remove the excessive zinc. The filtrate 
was concentrated under reduced pressure to remove the solvents. The crude material was 
purified by column chromatography on silica. The appropriate fractions, which were eluted 
with dichloromethane, were combined and evaporated under reduced pressure to yield the 
title compound as a light yellow solid (8.60 g, 18%).  
Rf: 0.51 (System E) 
δH(CDCl3): 1.37 (3 H, t, J = 7.2), 2.03 (3 H, s), 2.30 (3 H, s), 4.27 (2 H, q, J = 7.2), 6.67 (1 H, 
d, J = 2.0), 8.85 (1 H, br, s). 
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5-Phenyl-2,3,7,8-tetramethyldipyrromethane-1,9-dicarboxylate 122 [143] 
 
Boron trifluoride diethyl etherate (0.3 mL, 2.4 mmol) was added to a solution of ethyl 
3,4-dimethyl-2-pyrrolecarboxylate (2.00 g, 12.0 mmol) and benzaldehyde (0.60 mL, 5.9 
mmol) in dichloromethane (30 mL). The mixture was stirred under nitrogen for 24 h at room 
temperature and the products were then washed with saturated aqueous sodium bicarbonate 
solution (3×30 mL). The layers were separated and the aqueous layer was back extracted with 
dichloromethane (2×30 mL). The combined organic layers were further washed with brine 
(2×30 mL), dried (MgSO4) and then evaporated to dryness to give title compound as a yellow 
solid (1.85 g, 75%). 
δH(CDCl3):  1.34 (3 H, t, J = 7.2), 1.80 (3H, s), 2.27 (3 H, s), 4.27 (2 H, q, J = 7.2), 5.50 (1 H, 
s), 7.12 (2 H, d, J = 7.8), 7.31-7.38 (3 H, m), 8.22 (2 H, br, s).  
 
5-Phenyl-2,3,7,8-tetramethyldipyrromethane 123 [143] 
 
5-Phenyl-2,3,7,8-tetramethyldipyrromethane-1,9-dicarboxylate 122 (300 mg, 0.71 mmol) 
was dissolved in ethylene glycol (5 mL) containing sodium hydroxide (200 mg, 2.4 mmol), 
and the solution was heated at 220oC for 1 h. Upon cooling, the reaction mixture was diluted 
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with brine (15 mL) and extracted with dichloromethane (3×15 mL). The combined organic 
layers were washed with brine (15 mL), dried (MgSO4) and evaporated to dryness. The 
residue was further dried in vaccuo to give 5-phenyl-2,3,7,8-tetramethylpyrromethane as a 
black oil (170 mg, 81%). 
δH(CDCl3):  1.84 (12 H, s), 2.06 (12 H, s),  5.52 (1 H, s), 6.41 (2 H, d, J = 1.2), 7.17 (2 H, d, J 
= 8.0), 7.27-7.37 (3 H, m).  
 
2-Acetyl-5-chloropyrrole 126 [137] 
 
Sulfuryl chloride (0.75 mL, 9.3mmol) was added dropwise to a stirred solution of pyrrole 
(0.65 mL, 9.3 mmol) in anhydrous tetrahydrofuran (50 mL) in a nitrogen atmosphere at -78 
°C. The resulting solution was stirred at -78 °C for 3 h. In a separate flask, the acylating agent 
was prepared for the Vilsmeier reaction by mixing dimethylamide (0.67 mL, 10 mmol) and 
POCl3 (0.93 mL, 10 mmol) at 0°C. The mixture was stirred at room temperature until the 
Vilsmeier reagent salt was formed. Dichloromethane (25 mL) was added to the Vilsmeier 
reagent and then the solution was added dropwise over 10 min to the solution that contained 
the pyrrole substrate. The resulting solution was stirred at room temperature for 14 h and then 
heated under reflux for 15 min. An aqueous solution of sodium carbonate  (50 mL, 0.5 M) 
was added and the reaction mixture was heated under reflux for additional 30 min. Upon 
cooling, the products were extracted with diethyl ether (3×50 mL). The combined organic 
layers were washed with saturated aqueous sodium bicarbonate solution (2×100 mL) and 
N
H
Cl
O
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water (2×150 mL), dried (MgSO4) and evaporated under reduced pressure to dryness. The 
residue was purified by column chromatography on silica gel. The appropriate fractions, 
which were eluted with dichloromethane–hexane (30:70 v/v), were pooled and evaporated 
under reduced pressure to yield the target pyrrole derivative as a colorless solid (2.12 g, 74%). 
Rf: 0.31 (System E) 
δH(CDCl3):  2.41 (3 H, s), 6.15 (1 H, dd, J = 2.7, 3.9), 6.84 (1 H, dd, J = 2.7, 3.9), 9.25 (1 H, 
br, s). 
 
3-Chloro-4,4-difluoro-6-ethyl-5,7,8-trimethyl-4-bora-3a,4a-diaza-s-indacene 127 [137] 
 
To a solution of 2-acetyl-5-chloropyrrole 126 (325 mg, 2.3 mmol) in dichloromethane 
(10 mL) under nitrogen was added 3-ethyl-2,4-dimethylpyrrole 90 (310 µL, 2.3 mmol, 1 mol. 
equiv.) and the resulting solution was cooled (ice-water bath), followed by the addition of 
POCl3 (220 µL, 2.3 mmol, 1 mol. equiv.). After the reaction mixture was stirred at room 
temperature for 6 h (during this period the mixture became dark), triethylamine (3.2 mL, 23 
mmol) was added and the mixture was stirred for 10 min. Upon cooling (ice-water bath), 
boron trifluoride diethyl etherate (3.1 mL, 25 mmol) was added dropwise and the reaction 
mixture was stirred at room temperature for 1 h. The orange solution was diluted with diethyl 
ether (200 mL) and extracted with water (3×100 mL). The organic layer was dried (MgSO4) 
and concentrated under reduced pressure. The residue was then purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
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dichloromethane–hexane (70:30 v/v), were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (500 mg, 74%).  
Rf: 0.49 (System C) 
δH(CDCl3): 1.02 (3 H, t, J = 7.5), 1.78 (3 H, s), 3.92 (2 H, q, J = 7.5), 2.44 (3 H, s) 2.64 (3 H, 
s), 6.22 (1 H, d, J = 5.2), 7.05 (1 H, s, J = 2.7), 
δB(CDCl3):  0.58 (t, J = 33)  
 
Diphenyl-boronbromide 129 [144] 
 
Tetraphenyltin (10.0 g, 23.4 mmol) was placed in a flask and cooled to -70oC, followed 
by dropwise addition of boron tribromide (4.4 mL, 46.8 mmol) over 20 min while the 
temperature was maintained at -70 oC. After addition is complete, the reaction mixture was 
allowed to warm up to 0oC over a period of about 1 h. Stirring was continued for additional 2 
h and the reaction mixture was heated at 220oC for another 2 h. The mixture was then distilled 
to give the title compound as a light yellow oil (125-130 oC/2 mmHg 7.00 g, 61%). 
δH(CDCl3): 0.93 (3 H, t, J = 7.5), 1.09 (3 H, t, J = 7.5), 1.50 (3 H, s) 7.39-7.48 (10 H, m). 
δB(CDCl3):  66.4 
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3-Chloro-4,4-diphenyl-6-ethyl-5,7,8-trimethyl-4-bora-3a,4a-diaza-s-indacene 130  
 
To a solution of 2-acetyl-5-chloropyrrole 126 (400 mg, 2.8 mmol) in dichloromethane (8 
mL) under an atmosphere of nitrogen was added 2,4-dimethylpyrrole 90 (380 µL, 2.8 mmol, 1 
mol equiv.) and the resulting solution was cooled (ice-water bath), followed by addition of 
POCl3 (260 µL, 2.8 mmol, 1 mol. equiv.). After the solution was stirred at room temperature 
for 6 h (during this period the mixture became dark), triethylamine (1 mL, 7.2 mmol) was 
added and the mixture was stirred for 10 min. Diphenyl boronbromide (1.35 g, 5.5 mmol) was 
then added dropwise while the reaction mixture was cooled (ice-water bath). After the 
reaction mixture was stirred at room temperature for 1 h, the orange products were poured 
into diethyl ether (200 mL) and extracted with water (3×100 mL). The organic layer was dried 
(MgSO4) and concentrated under reduced pressure. The product was purified by flash column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–hexane (30:70 v/v), were combined and evaporated under reduced pressure 
to give the title compound as an orange solid (780 mg, 68%). 
Rf: 0.68 (System B) 
δH(CDCl3): 1.02 (3 H, t, J = 7.5), 1.78 (3 H, s), 3.92 (2 H, q, J = 7.5), 2.44 (3 H, s) 2.64 (3 H, 
s), 6.22 (1 H, d, J = 5.2), 7.05 (1 H, s, J = 2.7), 7.17-7.41 (10 H, m) 
δB(CDCl3):  0.43  
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4,4-Difluoro-4-bora-3a,4a-diaza-3-amino-1,6-diethyl-3,5,7-trimethyl-s-indacene 132 [138] 
 
A solution of sodium nitrite (180 mg, 2.6 mmol) in water (2 mL) was added dropwise to 
another solution of 2,4-dimethyl-3-ethylpyrrole (1 mL, 7.4 mmol) in acetic acid (30 mL) and 
acetic anhydride (30 mL), and the mixture was heated at 100 ºC for 2 h. The solvents were 
then removed under reduced pressure. The result product was diluted with dichloromethane 
(40 mL) and washed with saturated aqueous sodium bicarbonate solution (2×40 mL). The 
organic phase was dried (MgSO4) and evaporated to dryness under reduced pressure. The 
residue was dissolved in dichloromethane (40 mL) and triethylamine (2.8 mL, 20 mmol) 
followed after 30 min diphenyl boron bromide 129 (7.30 g, 30 mmol) were added. After 2 h, 
the reaction mixture was washed with water (3×40 mL), dried (MgSO4) and evaporated under 
reduced pressure. The residue was purified by column chromatography on silica gel. The 
appropriate fractions, which were eluted with dichloromethane–hexane (3:7 v/v), were pooled 
and concentrated under reduced pressure to give the title compound as a orange solid (230 
mg, 15%).   
Rf: 0.52 (System B) 
δH(CDCl3): 0.93 (3 H, t, J = 7.5), 1.09 (3 H, t, J = 7.5), 1.50 (3 H, s) 7.39-7.48 (10 H, m). 
δB(CDCl3):  -0.50  
 
N B N
NH2
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tert-Butyl uracil-1-yl acetate 149 [145] 
 
To a suspension of dried uracil (1.50 g, 13.5 mmol) and K2CO3 (1.90 g, 13.9 mmol) in 
DMF (20 mL) was added tert-butyl bromoacetate (2.1 mL, 17.8 mmol) at 0°C. The mixture 
was stirred for 15 h at room temperature and then filtered. The filtrate was evaporated under 
reduced pressure and the residue was diluted with water (60 mL) and extracted with ethyl 
acetate (3×50 mL). The combined organic phases were washed with water (50 mL), dried 
(MgSO4), and then evaporated under reduced pressure. The residue was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–hexane (6:4 v/v), were combined and evaporated under reduced pressure to 
afford the title compound (2.10 g, 69%) as a white amorphous powder.  
Rf: 2.8 (System E)  
δH(DMSO): 1.51 (9 H, s), 4.37 (2 H, s), 5.76 (1 H, d, J = 7.8), 7.12 (1 H, d, J = 7.8); 8.45 (1 
H, br, s) 
 
N
NH
O
O
O
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Uracil-1-yl acetic acid 150 [145] 
 
tert-Butyl uracil-1-yl acetate 149 (2.00 g, 8.9 mmol) was dissolved in TFA–CH2Cl2 
(30 mL, 1:1 v/v) and the mixture was stirred at room temperature for 3 h. The solvents were 
evaporated under reduced pressure and the crude residue was triturated with diethyl ether. The 
amorphous solid was filtered off to afford the title compound (1.40 g, 93%). 
δH(DMSO-d6): 3.65 (1 H, br, s), 4.41 (2 H, s), 5.59 (1 H, dd, J = 1.8 and 7.8), 7.61 (1H, d, J = 
7.8), 11.34 (1 H, s). 
 
N-Boc-ethylenediamine 152 [146] 
 
A solution of di-tert-butyl dicarbonate (2.12 g, 9.7 mmol) in dry dichloromethane (120 
mL) was added dropwise to a solution of ethylenediamine (6.7 mL, 0.1mol) in 
dichloromethane (250 mL) over a period of 6 h with vigorous stirring and cooling (ice-water 
bath). After the reaction mixture was stirred for additional 24 h at room temperature, the 
products were concentrated to ca. 150 mL. The resulting mixture was washed with aqueous 
sodium carbonate (3×50 mL). The organic phase was dried (MgSO4) and evaporated to 
dryness under reduced pressure and then further dried in vaccuo. The residue was purified by 
column chromatography on silica gel. The appropriate fractions, which were eluted with 
N
NH
O
O
OH
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concentrated aqueous ammonium hydroxide–methanol–chloroform (1:4:10, v/v), were 
combined and evaporated under reduced pressure to obtain the title compound as a colorless 
oil (1.45 g, 93%).  
δH(CDCl3): 1.37 (9 H, s), 1.59 (2 H, s), 2.72 (2 H, t, J = 6.4), 3.10 (2 H, q, J = 7.0), 5.12 (1 H, 
br, s). 
 
N-Benzyl-N’-Boc-ethylenediamine 153 [147] 
 
To a solution of N-Boc-ethylenediamine 145 (1.45 g, 9.0 mmol) in 1,4-dioxane (10 mL) 
at 0°C was added a solution of benzyl bromoacetate (1.43 mL, 0.9 mol) in 1,4-dioxane (20 
mL) over a period of 1 h, and the reaction mixture was stirred overnight. The solvent was 
evaporated under reduced pressure, and the residue was dissolved in water (50 mL) and 
extracted with ethyl acetate (3×50 mL). The combined organic phase was dried over MgSO4, 
and the solvent was removed under reduced pressure. The crude residue was purified by 
chromatography with dichloromethane–methanol (98:2, v/v) to afford the desired compound 
(2.10 g, 76%) as a colorless oil. 
Rf: 0.47 (System E) 
δH(CDCl3): 1.45 (9 H, s); 1.70 (1 H, br, s), 2.75 (2 H, t, J = 5.7), 3.20 (2 H, q, J = 5.4), 3.40 (2 
H, s), 5.06 (1 H, br, s), 5,17 (2 H, s), 7.36 (5 H, m). 
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Benzyl N-[2-(N-Boc-amino)ethyl]-N-(uracil-1-acetyl)glycinate 154 
 
N-Benzyl-N-Boc-ethylenediamine 153 (145 mg, 0.47 mmol) and uracil-1-yl acetic acid 
150 (88 mg, 0.52 mmol) were dissolved in DMF (8 mL) followed by addition of 
dicyclohexylcarbodiimide (120 mg, 0.58 mmol) and 4-dimethylaminopyridine (10 mg, 0.08 
mmol). The mixture was stirred for 12 h at room temperature and the precipitate was removed 
by filtration. The filtrate was concentrated under reduced pressure, and the residue was 
purified by column chromatography on silica gel. The appropriate fractions, which were 
eluted with dichloromethane–methanol (99:1, v/v), were pooled and evaporated under 
reduced pressure to give the title compound as a white solid (125 mg, 72%). 
Rf: 0.50 (System E) 
δH(DMSO-d6): 1.37 (2.25, s, rotamer 1), 1.38 (6.75 H, s, rotamer 2), 3.03 (0.5 H, q, J = 6.0, 
rotamer 1), 3.17 (1.5 H, q, J = 6.0, rotamer 2), 3.33 (0.5 H, t, J = 6.6, rotamer 1), 3.42 (1.5 H, 
t, J = 6.6, rotamer 2), 4.12 (1.5 H, s, rotamer 2), 4.38 (0.5 H, s, rotamer 1), 4.54 (0.5 H, s, 
rotamer 1), 4.72 (1.5 H, s, rotamer 2), 5.13 (1.5 H, s, rotamer 2), 5.21 (0.5 H, s, rotamer 1), 
5.57 (0.25 H, dd, J = 1.8 and 3.9, rotamer 1), 5.59 (0.75 H, dd, J = 1.8 and 7.8, rotamer 2), 
6.77 (0.25 H, t, J = 5.4, rotamer 1), 6.96 (0.75 H, t, J = 5.4, rotamer 2), 7.34-7.42 (6 H, m), 
11.32 (0.25 H, s, rotamer 1), 11.32 (0.75 H, s, rotamer 2). 
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N-[2-(N-Boc-amino)ethyl]-N-(uracil-1-acetyl)glycine 155 
 
Benzyl N-[2-(N-Boc-amino)ethyl]-N-(uracil-1-acetyl)glycinate 154 (100 mg, 0.27 mmol) 
was dissolved in methanol–ethyl acetate (6 mL, 5:1 v/v) followed by addition of 10% Pd on 
charcoal (7 mg). The reaction mixture was stirred in an atmosphere of H2 for 3 h at room 
temperature and then filtered through a pad of Celite. The filtrate was concentrated to give the 
title compound as a white solid in virtually quantitative yield (80 mg). 
δH(D2O): 1.35 (3.6 H, s, rotamer 1), 1.36 (5.4 H, s, rotamer 2), 3.19 (0.8 H, t, J = 6.0, rotamer 
1), 3.31 (1.2 H, t, J = 6.0, rotamer 2), 3.45 (0.8 H, t, J = 6.0, rotamer 1), 3.50 (1.2 H, t, J = 6.0, 
rotamer 2), 4.01 (0.8 H, s, rotamer 1), 4.06 (1.2 H, s, rotamer 2), 4.59 (0.8 H, s, rotamer 1), 
4.76 (1.2 H, s, rotamer 2), 5.8 (1 H, d, J = 7.8, rotamer 2), 7,47 (1 H, dd, J = 5.4 and 7.8) 
 
Diphenyl chloromethylphosphonate 157 [140]  
 
Chloromethylphosphonic dichloride 156 (3.00 g, 18.0 mmol) was dissolved in freshly 
distilled THF (40 mL) followed by dropwise addition of a solution of phenylmagnesium 
bromide in THF (36 mL, 1.0 M, 36 mmol) over 1 h. The resulting mixture was heated under 
reflux for 24 h. Upon cooling, the reaction was quenched by the addition of water (3 mL), and 
N OH
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volatiles were removed under reduced pressure. The residue was taken up in dichloromethane 
and washed with water (15 mL) and brine (15 mL). The organic layer was dried (MgSO4) and 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography, eluted with dichloromethane–methanol (99:1, v/v) to give the title 
compound as a white solid (2.57 g, 57%). 
δH(CDCl3): 4.03 (2 H, d, J = 6.3), 7.43-7.53 (6 H, m), 7.72-7.79 (4 H, m). 
δP(CDCl3): 28.2. 
Diphenyl acetylthiomethylphosphonate 158 [140]  
 
Diphenyl chloromethylphosphonate 157 (2.00 g, 8.0 mmol) was dissolved in THF (10 
mL) followed by addition of thioacetic acid (3.6 mL, 51.2 mmol). The resulting solution was 
cooled (ice-water bath) followed by dropwise addition of diisopropylethylamine (8.9 mL, 
51.2 mmol). The reaction mixture was then heated under reflux for 24 h while a stream of 
nitrogen gas is bubbled into the reaction mixture. Upon cooling, the volatiles were removed 
under reduced pressure. The resulting black oil was dissolved in dichloromethane (30 mL) 
and washed successively with hydrochloric acid (2 N, 15 mL), saturated aqueous sodium 
bicarbonate solution (15 L) and brine (15 mL). The organic layer was dried (MgSO4) and 
filtered. Activated charcoal was added to this solution, which was then heated under reflux for 
30 min. The activated charcoal was removed by filtration, and the filtrate was concentrated 
under reduced pressure, and the residue was purified by flash column chromatography, eluted 
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with dichloromethane–hexane (70:30 v/v), to give the title thioacetate (0.92 mg, 39%) as 
orange oil.  
δH(CDCl3): 2.24 (3 H, s), 3.75 (2 H, d, J = 8.4), 7.43-7.53 (6 H, m), 7.72-7.79 (4 H, m). 
δP(CDCl3): 28.9 
 
Acetylthiomethyl diphenylphosphine 159 [140]  
 
Diphenyl acetylthiomethyl phosphonate 158 (0.92 g, 3.2 mmol) was dissolved in 
anhydrous chloroform (10 mL) followed by addition of trichlorosilane (4.3 mL, 42.7 mmol). 
After the reaction mixture was stirred in an atmosphere of nitrogen for 72 h, the products 
were concentrated under reduced pressure. The residue was purified by flash chromatography, 
eluted with dichloromethane–hexane (30:70 v/v), to give the title compound as a black oil 
(0.42 g, 48%). 
δH(CDCl3): 2.31 (3 H, s), 3.41 (2 H, d, J = 3.6), 7.34-7.72 (10 H, m). 
δP(CDCl3): -15.7 
 
(Diphenylphosphino)methanethiol 160 [140]  
 
Acetylthiomethyl diphenylphosphine 159 (420 mg, 1.5 mmol) was dissolved in anhydrous 
methanol (15 mL), and argon gas was bubbled through the solution for 1 h. Sodium hydroxide 
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(180 mg, 3.0 mmol) was added, and the mixture was stirred under nitrogen for 2 h. Solvents 
were removed under reduced pressure, and the residue was taken up in dichloromethane (10 
mL) and washed with hydrochloric acid (2 N, 2×10 mL) and brine (10 mL). The organic layer 
was dried (MgSO4) and evaporated under reduced pressure. The residue was purified by flash 
chromatography, eluted with dichloromethane, to give the title compound as a clear oil (106 
mg, 30%). 
δH(CDCl3): 1.40 (1 H, q, J = 7.5), 3.41 (2 H, dd, J = 2.7 and 8.1), 7.39-7.48 (10 H, m). 
δP(CDCl3): -7.9. 
 
Uracil-PNA monomer 161 
 
Phosphinothiol 160 (106 mg, 0.46 mmol) and N-[2-(Boc-amino)ethyl]-N-(uracil-1-
acetyl)glycine 155 (185 mg, 0.50 mmol) were dissolved in DMF (10 mL) under an 
atmosphere of nitrogen, followed by addition of dicyclohexylcarbodiimide (103 mg, 0.50 
mmol). After the reaction mixture was stirred for 12 h at room temperature, the precipitate 
was removed by filtration. The filtrate was concentrated under reduced pressure, and the 
residue was purified by column chromatography on silica gel, eluted with dicloromethane–
methanol (99:1 v/v), to give the titled product as a white solid (110 mg, 42%). 
Rf: 0.58 (System E) 
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δH(CDCl3): 1.45 (3.2, s, rotamer 1), 1.46 (5.8 H, s, rotamer 2), 3.23 (2 H, m), 3.48 (2 H, m), 
3.56 (1.3 H, d, J = 4.2, rotamer 2), 3.61 (0.7 H, d, J = 4.3, rotamer 1), 4.20 (1.3 H, s, rotamer 
2), 4.25 (0.7 H, s, rotamer 1), 4.27 (0.7 H, s, rotamer 1), 4.59 (1.3 H, s, rotamer 2), 4.93 (0.35 
H, t, J = 6.0, rotamer 1), 5.35 (0.65 H, t, J = 6.0, rotamer 2), 5.72 (2 H, d, J = 7.6), 7.00 (0.3 
H, d, J = 7.8, rotamer 2), 7.11 (0.7 H, d, J = 7.8, rotamer 2), 7.34-7.46 (10 H, m), 8.72 (0.75 
H, s, rotamer 2), 8.77 (0.35 H, s, rotamer 1). 
δP(CDCl3): -13.9 (0.35 P, rotamer 1), -14.9 (0.65 P, rotamer 2) 
 
Benzyl 2-azidoethylglycine 164 
 
To a solution of 2-aminoethyl chloride hydrochloride salt (1.00 g, 8.7 mmol) in water (10 
mL) was added sodium azide (1.70 g, 25.8 mmol) and the reaction mixture was heated at 
80oC for 15 h. The solution was concentrated under reduced pressure and then further dried 
under high vacuum. The residue was then co-evaporated with toluene (2×8 mL) and dry 
toluene (5 mL). The resulting solid was suspended in DMF (20 mL), followed first by 
addition of the Hunig’s base (3.0 mL, 16.5 mmol) and then dropwise addition of benzyl 2-
bromoacetate (1.1 mL, 7.0 mmol). The reaction mixture was stirred for 6 h at 60oC and then 
diluted with water (50 mL) and extracted with ethyl acetate (3×50 mL). The organic phase 
was dried (MgSO4) and concentrated under reduced pressure. The residue was purified by 
flash chromatography, eluted with dicloromethane–methanol (99:1 v/v), to give the title 
compound (0.87 mg, 53%) as a light yellow oil.  
Rf: 0.4 (System E) 
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δH(DMSO): 2.31 (1 H, br, s), 2.75 (2 H, t, J = 6.0), 3.32 (2 H, t, J = 6.0), 3.44 (2 H, s), 5.13 (2 
H, s), 7.30-7.40 (m, 5 H, Ar). 
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U-PNA monomer (2) 165 
 
Benzyl 2-azidoethylglycine 164 (220 mg, 0.94 mmol) and uracil-1-yl acetic acid 150 (112 
mg, 1.0 mmol) were dissolved in DMF (3 mL) followed by addition of 
dicyclohexylcarbodiimide (206 mg, 1.0 mmol) and DMAP (12 mg, 0.10 mmol). After the 
reaction mixture was stirred for 12 h at room temperature, the precipitate was removed by 
filtration. The filtrate was concentrated under reduced pressure, and the residue was purified 
by column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (99:1 v/v), were combined and evaporated to get the title 
compound (472 mg, 54%) as a white solid. 
Rf: 0.63 (System E) 
δH(DMSO): 3.50 (2 H, m), 3.58 (2 H, m), 4.16 (1.1 H, s, rotamer 2), 4.30 (0.9 H, s, rotamer 
1), 4.46 (0.9 H, s, rotamer 1), 4.70 (1.1 H, s, rotamer 2), 5.16 (1.1 H, s, rotamer 2), 5.23 (0.9 
H, s, rotamer 1), 5.70 (0.45 H, d, J = 7.8, rotamer 1), 5.71 (0.55 H, d, J = 7.8, rotamer 2), 7.08 
(0.45 H, d, J = 7.8, rotamer 2), 7.18 (0.55 H, d, J = 7.8, rotamer 2), 7.31-7.37 (5 H, m), 9.95 
(1 H, br, s). 
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